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ABSTRACT
ATP competitive inhibitors of DNA gyrase and topoisomerase IV have great therapeutic potential,
but none of the described synthetic compounds has so far reached the market. To optimise the
activities and physicochemical properties of our previously reported N-phenylpyrrolamide
inhibitors, we have synthesised an improved, chemically variegated selection of compounds and
evaluated them against DNA gyrase and topoisomerase IV enzymes, and against selected Gram-
positive and Gram-negative bacteria. The most potent compound displayed IC50 values of 6.9 nM
against Escherichia coli DNA gyrase and 960 nM against Staphylococcus aureus topoisomerase
IV. Several compounds displayed minimum inhibitory concentrations (MICs) against Gram-
positive strains in the 1-50 µM range, one of which inhibited the growth of Enterococcus faecalis,
Enterococcus faecium, S. aureus and Streptococcus pyogenes with MIC values of 1.56 µM, 1.56
µM, 0.78 µM and 0.72 µM, respectively. This compound has been investigated further on
methicillin-resistant S. aureus (MRSA) and on ciprofloxacin non-susceptible and extremely drug
resistant strain of S. aureus (MRSA VISA). It exhibited the MIC value of 2.5 µM on both strains,
2and MIC value of 32 µM against MRSA in the presence of inactivated human blood serum. Further
studies are needed to confirm its mode of action.
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ABBREVIATIONS
ACN, acetonitrile; ATCC, American type culture collection; ATR, attenuated total reflectance;
CFU, colony-forming unit; CLSI, Clinical and Laboratory Standards Institute; DCM,
dichloromethane; DMF, dimethylformamide; DIAD, diisopropylazodicarboxylate; GyrA, DNA
gyrase A; GyrB, DNA gyrase B; HepG2, human hepatocellular carcinoma; HPLC, high pressure
liquid chromatography; HUVEC, human umbilical vein endothelial cells; MIC, minimum
inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; MTS, 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; NMM, N-
methylmorpholine; PAβN, phenylalanine-arginine β-naphthylamide; ParC, topoisomerase IV
subunit A; ParE, topoisomerase IV subunit B; PC, principal component; RA, residual activity;
TBTU, N,N,N′,N′-tetramethyl-O-(benzotriazol-1-yl)uroniumtetrafluoroborate; THF,
tetrahydrofuran;  topo IV, topoisomerase IV; VISA, vancomycin-intermediate Staphylococcus
aureus.
INTRODUCTION
Antibiotic-resistant infections kill an estimated 700,000 people each year [1]. Recently, the World
Health Organization (WHO) has issued a list of drug-resistant bacteria that pose the greatest threat
to human health and thus present a big challenge for antibacterial drug development. Between 2010
and 2015, the US Food and Drug Administration (FDA) approved only eight new antibacterials,
and seven of them showed similar mechanism of action to the previously approved antibiotics [2].
Thus, new antibacterial agents with novel mechanisms of action are needed.
Bacterial topoisomerases, DNA gyrase and topoisomerase IV (topo IV), are enzymes that catalyse
changes in DNA topology [3]. There are two types of topoisomerases: type I that catalyse single-
3strand breaks, and type II that are responsible for the transient break of two strands of DNA [4].
DNA gyrase and topoisomerase IV belong to type II topoisomerases and display high structural
and functional similarities. They are both heterotetrameric enzymes composed of two pairs of
subunits. DNA gyrase is composed of two GyrA and two GyrB subunits, while topoisomerase IV
is  composed  of  two ParC and  two ParE subunits.  GyrA and  GyrB subunits  of  DNA gyrase  are
similar in amino acid sequence to ParC and ParE subunits of topoisomerase IV, respectively [5].
The main function of GyrA/ParC is cleavage and reunion of the DNA molecule, whereas
GyrB/ParE binds ATP, providing through its hydrolysis, the energy for the ligation process. DNA
gyrase introduces negative supercoils in DNA during replication, whereas topoisomerase IV is
involved in the decatenation of the two daughter chromosomes after replication [6].
Being absent in eukaryotes and at the same time an essential enzyme for bacterial survival, DNA
gyrase has become an attractive target for the development of antibacterials. Drugs targeting DNA
gyrase exert their antibacterial activity via two main mechanisms. The first is stabilisation of the
covalent enzyme–DNA complex, i.e. gyrase poisoning. This mechanism is typical of the quinolone
class  of  antibacterials,  with  ciprofloxacin  as  the  most  distinctive  representative.  The  second
mechanism involves blocking the ATP binding site of DNA gyrase B. The aminocoumarin natural
products novobiocin and clorobiocin are examples of catalytic inhibitors that target the ATP
binding site on the GyrB/ParE subunit [4].
Fluoroquinolones have been used extensively in the clinic, resulting in the development of many
fluoroquinolone-resistant bacterial strains [7]. The growing resistance problem together with some
serious side effects has stimulated the search for new inhibitors which target ATP binding site on
DNA gyrase and topoisomerase IV. The only ATPase inhibitor that has been used in the clinic is
novobiocin, which was indroduced in the 1960s but was later withdrawn from the market due to
its  toxicity  and  weak  potency  [6,  8].  More  recently,  many  structurally  diverse  classes  of  GyrB
inhibitors have been discovered, such as pyrrolamides [9], benzothiazoles [10], ethyl ureas [11],
N-phenylpyrrolamides [12-15] and pyrimidoindoles [16] (Figure 1), which possess potent on-target
and antibacterial activities but have some liabilities, such as unfavourable physicochemical
properties or toxicity issues.
4Figure 1. Representative ATP competitive DNA gyrase and topoisomerase IV inhibitors, and their
IC50 and MIC values.
RESULTS AND DISCUSSION
Design. Using our previous N-phenylpyrrolamide inhibitors as starting points [12-15], and having
at disposal the crystal structure of E. coli GyrB in complex with one of our inhibitors (PDB code:
4ZVI) [12], optimised N-phenylpyrrolamides were prepared with improved on-target and
antibacterial activities. The three structural types of compounds (types I-III, Figure 2) possess
modifications on the central part and right-hand sides of the molecules. In all three types of
compounds, a hydrogen bond donor-acceptor structural feature was maintained on the left-hand
side of the molecules. This part of the inhibitors is fundamental for establishing hydrogen bonding
with Asp73 (E. coli numbering) and a structurally conserved water molecule (Figure 2).
Additionally, the substituted pyrrole moiety makes important hydrophobic contacts with the
hydrophobic pocket composed of Val71, Val43, Val167, and Ala47, which is also the binding site
for the clorobiocin 5-methylpyrrole moiety [6]. Two differently substituted pyrrole-2-carboxylic
acids were used for preparing the inhibitors: 4,5-dibromopyrrole-2-carboxylic acid and 3,4-
dichloro-5-methylpyrrole-2-carboxylic acid. The latter was selected preferentially because the
5chlorine  atoms  are  slightly  smaller  than  the  bromine  atoms  and  thus  fit  better  into  the  adenine
binding pocket not only of E. coli DNA gyrase, but also into the slightly smaller binding pockets
of S. aureus DNA gyrase and topoisomerase IV [17].
On  the  right-hand  side  of  the  molecules  we  introduced  acidic  groups  (e.g.  carboxylic  acid-
containing groups, such as glycine and (S)- or (R)-alanine) capable of forming interactions with the
positively charged Arg136 residue, or moieties (e.g. 1,3,4-oxadiazol-2-thione and 5-oxotetrazole)
capable of forming cation-π interactions with the Glu50-Arg76 salt bridge and hydrogen bonds
with Arg136 side chain. The 1,3,4-oxadiazol-2-thione and 5-oxotetrazole rings were introduced as
bioisosteres of carboxylic acid group. The lower acidity of these moieties compared to carboxylic
acid was expected to improve entry into bacteria and, consequently, result in better antibacterial
activity [18].
Type I compounds contain an alkoxy substituent at the ortho position to the substituted amino
group of the central benzene ring (substituent X, Figure 1). The size of this substituent was varied
from the bulkier piperidin-4-yloxy, through pyrrolidin-3-yloxy to the smaller isopropoxy group.
An amino group-containing heterocycle was selected as substituent X for three reasons: i) the
possibility of forming hydrophobic contacts with the lipophilic floor of the enzyme (amino acid
residues Ile94, Ile78) [14], ii) the possibility of forming additional hydrogen bonds through the ring
NH group, and iii) the presence of a positive charge that has recently been associated with an
increased level of accumulation in E. coli [19]. It was previously shown by docking studies that
the nitrogen atom could form an H-bond with amino acid residue Ala100 that is a part of the flexible
loop between amino acid residues Gly97-Ser108 [15]. Moreover, because of the ionic character of
the  amino  group,  the  water  solubility  of  these  compounds  is  likely  to  improve.  In  the  case  of
isopropoxy substituent, only the interactions with the lipophilic floor are possible, but the
possibility of establishing H-bond with Ala100 is lost.
Type II compounds, unlike type I, do not contain substituents at the ortho position to the amino
group of the central benzene ring. The focus in this series was given on the right part of the
molecules, to which chemically diverse groups were introduced, such as sulphonamides, acyl
sulfonamides, aliphatic nitriles, malonates or a 5-oxotetrazole ring (Figure 2). Sulfonamides, acyl
sulphonamides and 5-oxotetrazole are well-known examples of carboxylic acid isosteres, and have
been of fundamental importance in the discovery of novel therapeutics [20] [21]. Nitriles are
attractive moieties in medicinal chemistry because of their strong dipole moment and small size,
6that  facilitate  polar  interactions  in  which  the  nitrile  group acts  as  a  hydroxyl  or  carboxyl  group
isostere [22]. Malonic ester derivatives were designed in order to investigate how two carboxylate
groups affect the interaction with the Arg136 residue.
In type III compounds, the central phenyl ring was replaced by a bicyclic scaffold to afford a
quinolone-like structure or a substituted indole group (Figure 2). To this heterocycle, a carboxylic
group was attached to establish ionic bonds with Arg136. With the quinolone derivative, our goal
was to prepare a molecular hybrid in which the left-hand side of the molecule is represented by the
N-phenylpyrrolamide DNA gyrase B-binding motif, and the right-hand side is represented by the
4-oxo-quinoline-2-carboxlic acid moiety, a known DNA gyrase A binder (Figure 3). Targeting
both active sites with the same molecule could result in synergistic activity and in a reduced
probability of development of bacterial resistance [6].
7Figure 2. Design of three structural types (I-III) of N-phenylpyrrolamides as DNA gyrase B
inhibitors, based on the co-crystal structure of the inhibitor A – GyrB (E. coli) (PDB code: 4ZVI
[12]).
Figure 3. Design of a molecular hybrid inhibitor by merging the left side portion of N-
phenylpyrrolamide as a GyrB binder and nalidixic acid as a GyrA binder.
Chemistry. The synthesis of type I compounds (8a-d, 9a-d and 10a-b) is presented in Scheme
1. In the first step, 3-hydroxy-4-nitrobenzoic acid (1) was reacted with thionyl chloride and
methanol to afford the corresponding methyl ester 2. The hydroxyl group of 2 was alkylated with
N-Boc-4-hydroxypiperidine under Mitsunobu conditions to afford the intermediate 3. The alkaline
hydrolysis of ester 3 gave the carboxylic acid 4 that was coupled with glycine methyl ester, or (S)-
or (R)-alanine methyl ester using N,N,N',N'-tetramethyl-O-(benzotriazol-1-
yl)uroniumtetrafluoroborate (TBTU) promoted coupling to yield compounds 5a-c. After catalytic
hydrogenation, the resulting anilines 6a-c were coupled with 4,5-dibromopyrrole-2-carboxylic acid
or 3,4-dichloro-5-methylpyrrole-2-carboxylic acid. The obtained esters 7a-d underwent alkaline
hydrolysis to afford the N-Boc protected compounds 8a-d that were, in turn, reacted with 1 M HCl
in acetic acid or with 4 M HCl in 1,4-dioxane to give the target compounds 9a-d. Additionally,
esters 7c-d underwent the removal of Boc protecting group yielding the products 10a-b.
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Scheme 1. Reagents and conditions: (a) thionyl chloride, MeOH, 0 °Cà rt, 15 h; (b) PPh3, DIAD,
N-Boc-4-hydroxypiperidine, anhydrous THF, rt, 15 h; (c) 1 M NaOH, MeOH, rt, 15 h; (d) glycine
methyl ester hydrochloride (for the synthesis of 5a) or (S)- or (R)-alanine methyl ester
hydrochloride (for the synthesis of 5b-c), TBTU, NMM, anhydrous DMF, 60 °C, 12 h; (e) H2,
Pd-C,  MeOH,  rt,  5  h;  (f) i) 4,5-dibromopyrrole-2-carboxylic acid or 3,4-dichloro-5-
methylpyrrole-2-carboxylic acid, oxalyl chloride, anhydrous CH2Cl2, rt, 15 h, then ii) 6a-c,
anhydrous pyridine, anhydrous CH2Cl2, rt, 15 h; (g) 1 M NaOH, MeOH/THF, rt, 15 h (for the
synthesis of 8a-b) or 1 M LiOH, MeOH/THF, rt, 15 h (for the synthesis of 8c-d); (h) 1 M HCl in
acetic acid, DMF, rt, 8 h (for the synthesis of 9a-b) or 4 M HCl in 1,4-dioxane, rt, 4 h (for the
synthesis of 9c-d); (i) 4 M HCl in 1,4-dioxane, rt, 4 h.
9The synthesis of compounds 16, 17 and 18, containing a pyrrolidine moiety, is shown in Scheme
2. The pathway is similar to the one described for the preparation of compounds 8a-d, 9a-d and
10a-b (Scheme 1), except that instead of N-Boc-4-hydroxypiperidine, (R)-N-Boc-3-pyrrolidinol
was used as the alcohol moiety for the Mitsunobu reaction in the synthesis of compound 11.
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Scheme 2. Reagents and conditions: (a) PPh3, DIAD, (R)-N-Boc-3-pyrrolidinol, anhydrous THF,
rt, 15 h; (b) 1 M NaOH, MeOH, rt, 15 h; (c) glycine methyl ester hydrochloride, TBTU, NMM,
anhydrous DMF, 60 °C, 12 h; (d) H2, Pd-C, MeOH, rt, 5 h; (e) i) 3,4-dichloro-5-methylpyrrole-2-
carboxylic acid, oxalyl chloride, anhydrous CH2Cl2, rt, 15 h, then ii) 14, anhydrous pyridine,
anhydrous CH2Cl2, rt, 15 h; (f) 1 M NaOH, MeOH/THF, rt, 15 h (g) 1M HCl in acetic acid, DMF,
rt, 8 h; (h) 4 M HCl in 1,4-dioxane, rt, 4 h.
The synthesis of compound 25 is shown in Scheme 3. The isopropoxy derivative 19, obtained under
Mitsunobu conditions from compound 2, underwent alkaline hydrolysis to afford the acid 20. The
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coupling of 20 with (R)-alanine methyl ester hydrochloride, followed by catalytic hydrogenation,
gave the aniline 22 which was reacted with 3,4-dichloro-5-methylpyrrole-2-carbonyl chloride to
afford the ester 23. The hydrazinolysis of 23 yielded 24 which was reacted with 1,1′-
thiocarbonyldiimidazole to give the final product 25.
Scheme 3. Reagents and conditions: (a) PPh3, DIAD, isopropanol, anhydrous THF, rt, 15 h; (b) 1
M NaOH, MeOH, rt, 15 h; (c) (R)-alanine methyl ester hydrochloride, TBTU, NMM, anhydrous
DMF, 60 °C, 12 h; (d) H2, Pd-C, MeOH, rt, 5 h; (e) i) 3,4-dichloro-5-methylpyrrole-2-carboxylic
acid, oxalyl chloride, anhydrous CH2Cl2, rt, 15 h, then ii) 22, anhydrous pyridine, anhydrous
CH2Cl2, rt, 15 h; (f) hydrazine hydrate, dry MeOH/dry THF, reflux, 15 h; (g) 1,1′-
thiocarbonyldiimidazole, 1,4-dioxane/DMF, 100 °C, 15 h.
The synthesis of type II compounds 27, 29, 34 and 39 is presented in Scheme 4. Compounds 27
and 29 were obtained by coupling 3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl chloride, with
sulfanilamide (26) and sulfathiazole (28), respectively. For the preparation of compound 34, 4-
nitrobenzenesulfonyl chloride (30) was mixed with glycine methyl ester hydrochloride in the
presence of triethylamine to give 31, which underwent catalytic reduction to yield 32. The final
product 34 was obtained after alkaline hydrolysis of the ester 33, obtained by coupling of 32 and
3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl chloride.
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For the synthesis of compound 39, methanesulfonyl chloride (35)  was  reacted  with  gaseous
ammonia to obtain methanesulfonamide (36). Compound 36 was then mixed with 4-nitrobenzoyl
chloride in the presence of triethylamine to obtain 37 which, after catalytic hydrogenation,
generated compound 38 that was coupled with 3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl
chloride to yield the acyl sulfonamide 39.
Scheme 4. Reagents and conditions: (a) i) 3,4-dichloro-5-methylpyrrole-2-carboxylic acid, oxalyl
chloride, anhydrous CH2Cl2, rt, 15 h, then ii) 26, anhydrous pyridine, anhydrous THF, rt, 15 h for
the synthesis of 27 or ii) 28, anhydrous pyridine, anhydrous THF, rt, 15 h for the synthesis of 29;
(b) glycine methyl ester hydrochloride, triethylamine, CH2Cl2,  0  °C à rt,  12  h;  (c)  H2, Pd-C,
MeOH, rt, 3 h; (d) i) 3,4-dichloro-5-methylpyrrole-2-carboxylic acid, oxalyl chloride, anhydrous
CH2Cl2, rt, 15 h, then ii) 32, anhydrous pyridine, anhydrous THF, rt, 15 h; (e) 1 M NaOH,
MeOH/THF, rt, 15 h; (f) gaseous ammonia, anhydrous THF, 0 °C, 0.5 h; (g) 4-nitrobenzoyl
chloride, triethylamine, anhydrous CH2Cl2, 0 °Cà rt, 12 h; (h) i) 3,4-dichloro-5-methylpyrrole-2-
carboxylic acid, oxalyl chloride, anhydrous CH2Cl2, rt, 15 h, then ii) 38, anhydrous pyridine,
anhydrous THF, rt, 15 h.
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The synthesis of compounds 43a-b, 46a-b and 50 is shown in Scheme 5. For the preparation of the
aliphatic nitriles 43a-b, aminoacetonitrile hydrochloride was firstly coupled with 4-nitro benzoic
acid  (40) using TBTU methodology. The nitro group of the obtained intermediate 41 was then
reduced to give compound 42 which was reacted with 4,5-dibromo-1H-pyrrole-2-carbonyl chloride
or 3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl chloride to afford the final products 43a-b. The
malonates 46a-b were prepared by reacting 40 with diethyl aminomalonate hydrochloride via
TBTU methodology. Compound 44 underwent catalytic hydrogenation to give the substituted
aniline 45 which was reacted with 4,5-dibromo-1H-pyrrole-2-carbonyl chloride or 3,4-dichloro-5-
methyl-1H-pyrrole-2-carbonyl chloride to afford the final compounds 46a or 46b. The hydrolysis
of ethyl ester groups of 46a-b was unsuccessful as decarboxylation was observed. The 5-
oxotetrazole derivative 50 was prepared by mixing 4-nitrobenzoyl chloride (47) with
azidotrimethylsilane to give compound 48 via initial acylazide formation and subsequent Curtius
rearrangement [23]. The following catalytic hydrogenation of 48 and the coupling of the amine 49
with 3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl chloride yielded the final compound 50.
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Scheme 5. Reagents and conditions: (a) aminoacetonitrile hydrochloride, TBTU, NMM,
anhydrous DMF, 60 °C, 12 h; (b) H2, Pd-C, MeOH, rt, 3 h; (c) i) 4,5-dibromopyrrole-2-carboxylic
acid or 3,4-dichloro-5-methylpyrrole-2-carboxylic acid, oxalyl chloride, anhydrous CH2Cl2, rt, 15
h, then ii) 42, anhydrous pyridine, anhydrous CH2Cl2,  rt,  15  h  (for  the  synthesis  of 43a-b); (d)
diethyl aminomalonate hydrochloride, TBTU, NMM, anhydrous DMF, 60 °C, 12 h; (e) H2, Pd-C,
EtOH,  rt,  3  h;  (f) i) 4,5-dibromopyrrole-2-carboxylic acid or 3,4-dichloro-5-methylpyrrole-2-
carboxylic acid, oxalyl chloride, anhydrous CH2Cl2, rt, 15 h, then ii) 45, anhydrous pyridine,
anhydrous CH2Cl2, rt, 15 h (for the synthesis of 46a-b); (g) azidotrimethylsilane, 90 °C, 12h; (h)
3,4-dichloro-5-methylpyrrole-2-carboxylic acid, oxalyl chloride, anhydrous CH2Cl2, rt, 15 h, then
ii) 49, anhydrous pyridine, anhydrous CH2Cl2, rt, 15 h.
The synthesis of type III compounds 57 and 61 is presented in Scheme 6. For the synthesis of
compound 57 we employed the Gould-Jacobs route [24]. 3-Nitroaniline (51) was first mixed with
diethyl ethoxymethylenemalonate to give the derivative 52. This was then cyclized in diphenyl
ether as a solvent to afford compound 53, which was subsequently alkylated with ethyl bromide to
form 54. The nitro group of 54 was reduced with catalytic hydrogenation and the resulting aniline
55 was coupled with 3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl chloride to give the ester 56.
Compound 56 underwent alkaline hydrolysis to yield the final quinolone 57. For the synthesis of
the indole derivative 61, compound 58 was first reduced to the corresponding amine 59, which was
then reacted with 3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl chloride to give the ester 60.
Finally, the alkaline hydrolysis of ethyl ester group of 60 afforded the final product 61.
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Scheme 6. Reagents and conditions: (a) diethyl ethoxymethylenemalonate, 90 °C, 3 h; (b) diphenyl
ether, 260 °C, 2.5 h; (c) ethyl bromide, K2CO3, anhydrous DMF, 70 °C, 12 h; (d) H2, Pd-C, EtOH,
rt, 3 h (e) i) 3,4-dichloro-5-methylpyrrole-2-carboxylic acid, oxalyl chloride, anhydrous CH2Cl2,
rt, 15 h, then ii) 55, anhydrous pyridine, anhydrous CH2Cl2,  rt,  15 h; (f)  1 M NaOH, EtOH/1,4-
dioxane, rt, 5 h; (g) i) 3,4-dichloro-5-methylpyrrole-2-carboxylic acid, oxalyl chloride, anhydrous
CH2Cl2, rt, 15 h, then ii) 59, anhydrous pyridine, anhydrous CH2Cl2, rt, 15 h.
Inhibitory Activities Against DNA Gyrase and Topoisomerase IV. Thirty-five new compounds
were synthesized and evaluated for their inhibitory activity against E. coli DNA  gyrase  in  a
supercoiling assay. The results are presented either as residual activities (RAs) of the enzyme at 1
µM of compounds or as IC50 values (Tables 1-3). The most potent compounds were additionally
evaluated against S. aureus DNA gyrase, and against E. coli and S. aureus topoisomerase IV (Table
4). To determine possible binding modes of compounds, molecular docking of all tested
compounds to the E. coli GyrB binding site was performed using GOLD software [25] and the
results are presented in Supporting information.
Thirteen compounds (8b, 8c, 9a-d, 10a-b, 16, 17, 18, 50 and 61) showed potent inhibition of E.
coli DNA gyrase with low nanomolar inhibitory values (IC50 < 100 nM). Twelve of these inhibitors
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contained the 3,4-dichloro-5-methyl-1H-pyrrole moiety in the left-hand side of the molecule,
which thus proved to be more optimal than 4,5-dibromo-1H-pyrrole group. In general, carboxylic
acid derivatives possessed stronger activity than the corresponding methyl ester derivatives. As an
example of this trend, the carboxylic acid 8b exhibited an IC50 value of 86 nM whereas the ester
7b was inactive (RA = 100%). The reason for this difference stems from the ability of carboxylic
acids (and not of esters) to form salt bridge with Arg136 residue (Figure 1S of Supporting
information).
Type I inhibitors with carboxylic groups on the right-hand side of the molecule and amino group-
containing heterocycles attached at the ortho position to the amino group on benzene ring
(substituent X, Figure 1) (9a, 9b, 9c, 9d and 17) proved to be the most potent inhibitors of DNA
gyrase within the series (IC50 ≤ 31 nM). Piperidin-4-yloxy and pyrrolidin-3-yloxy substituents are
most probably forming favourable interactions with the hydrophobic floor of the enzyme.
Moreover, the amino group of these heterocycles can potentially form a hydrogen bond with
Ala100 that is part of the flexible loop between amino acid residues Gly97-Ser108, as predicted by
docking of compound 9d (IC50 =  6.9  nM) to  the  DNA gyrase  B active  site  (Figure  1S),  and  as
reported by our research group for a related compound [15]. Interestingly, also some derivatives
containing a combination of N-Boc-protected amino group and free carboxylic acid group on the
right-hand side, e.g. compounds 8b, 8c, 8d and 16, showed good activity against E. coli gyrase
(IC50 ≤ 100 nM). Also, the positively charged ester derivatives 10a, 10b and 18 showed good
activities on the enzyme with IC50 values of 40 nM, 48 nM and 74 nM, respectively. On the other
hand, compounds with simultaneous presence of the methyl ester group on the right-hand side and
N-Boc-protected heterocycle (7c, 7d and 15) were inactive (RA = 83%, 94% and 93%
respectively). The activities of pyrrolidine derivatives were comparable to the activities of their
piperidine-containing counterparts, as can be seen by comparing, e.g. pyrrolidine 17 (IC50 = 31
nM) to piperidine 9b (IC50 = 17 nM) and pyrrolidine 16 (IC50 = 92 nM) to piperidine 8b (IC50 = 86
nM). Among the isopropoxy derivatives, compound 25 with a 1,3,4-oxadiazol-2-thione ring
attached to the right-hand side, displayed a significantly higher activity (IC50 = 190 nM) compared
to its corresponding hydrazide 24 (RA = 89%) or ester analogue 23 (RA = 87%). Compounds 9c
(IC50 = 9.9 nM) and 9d (IC50 = 6.9 nM) with (S)- and (R)-alanine groups attached to the right-hand
side proved to be on the same order of potency as their glycine relative 9b (IC50 = 17 nM). There
were no marked differences in activities between the (S)- and (R)-alanine isomers.
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Overall, type II inhibitors were less potent than type I compounds, which is probably due to the
absence of substituents at the ortho position to the amino group on the benzene ring. The focus in
type II compounds was to study the effects of different substituents on the right-hand side of the
molecule. Three compounds - acyl sulfonamide 39, aliphatic nitrile 43b and 5-oxotetrazole 50 -
displayed good IC50 values of 160 nM, 410 nM and 77 nM, respectively. Owing to the acidity of
its NH group, acyl sulphonamides are commonly used as carboxylic acid isosteres [26]. Moreover,
compounds containing this functional group often show improved oral availability, metabolic
stability and potency compared to the parent carboxylic acids [27]. The nitrile 43b and its dibromo
pyrrole analogue 43a were synthesised because of the important roles that nitrile groups have as
hydrogen bond acceptors [28]. The nitrile functionality can act as a carboxylic acid isostere, which
has been exploited in the design of vildagliptin [22]. Nitrile-containing quinolones with good
potency and safe therapeutic profiles were also reported [29]. Similarly, 5-oxotetrazole derivative
50 was prepared as a carboxylic acid isostere. The NH group at the 4-position of 5-oxotetrazole
has  a  similar  pKa  value  to  the  NH  of  tetrazole  [21].  Given  the  smaller  size  of  compound 50
compared to type I inhibitors, it is expected that the 5-oxotetrazole ring is making interactions with
Arg76 rather than Arg136. Other compounds of the type II series, such as sulfonamides 27, 29, 33
and 34 (RA = 82%, 100%, 87% and 87% respectively), and malonic ester derivatives 46a (RA =
78%) and 46b (IC50 =  7700 nM),  were  not  active  on E. coli DNA gyrase. This can perhaps be
explained with the weaker acidity of sulfonamides (pKa range: 7.3-9.7 [30]) compared to
carboxylic acids, while the weak inhibitory values of malonic ester derivatives are in line with
those of most esters in the type I series and additionally suggest that the malonic functionality could
be too bulky to establish strong interactions with Arg136.
The type III compounds contain a quinolone-like structure (56 and 57) or a substituted indole
moiety (60 and 61) and are more rigid than the compounds belonging to type I and II series. Among
the two quinolones, the ester 56 interestingly  showed stronger  activity  (IC50 =  53  nM) than  the
corresponding carboxylic acid analogue 57 (IC50 = 1400 nM). The opposite was observed in the
indole series, where the carboxylic acid 61 displayed excellent inhibitory activity (IC50 = 98 nM)
whereas the ethyl ester analogue 60 was completely inactive (RA = 100%).
Some of the prepared compounds displayed promising activities also on DNA gyrase from S.
aureus and on topoisomerase IV from E. coli and S. aureus, although the activities were generally
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lower than those on E. coli DNA gyrase (Table 4). Compounds 9c and 9d, that were the most potent
on E. coli DNA gyrase (IC50 = 9.9 nM and IC50 = 6.9 nM, respectively), were also among the most
potent inhibitors of these three enzymes. In particular, derivative 9c displayed a nanomolar activity
against S. aureus DNA gyrase (IC50 = 99 nM) and a good activity against topoisomerase IV from
S. aureus (IC50 = 689 nM). Compound 9d, the D-enantiomer of 9c, showed slightly weaker activity
on the S. aureus gyrase, but was comparably active on all other tested enzymes. Similarly as for E.
coli gyrase, zwitterionic compounds 9b-d and 17 were  the  most  potent  in  the  series,  which
underlines the importance of the carboxylic moiety on the right-hand side of the molecules and the
amino group-containing heterocycles on the central benzene ring for the binding affinity. Because
of the slightly bigger size of bromine atoms compared to chlorine atoms, and because of the smaller
size of the ATP binding pocket of S. aureus gyrase and of topo IV, the dibromopyrrole derivative
9a was less active against those enzymes. In addition to zwitterionic compounds, also the methyl
ester derivatives 10a, 10b and 18 showed moderate activities, with L-alanine derivative 10a being
the best. Derivatives containing an alanine group attached to the right-hand side (8c, 8d, 9c, 9d,
10a-b and 25) were generally more potent than their glycine counterparts, but glycine-containing
compound 9b displayed the best activity against E. coli topoisomerase IV among all tested
compounds, with IC50 value of 7200 nM. Compound 25 with an isopropoxy group on the benzene
ring, showed much weaker activity than compounds with piperidin-4-yloxy (e.g. 8b-c, 9b-d and
10a) and pyrrolidin-3-yloxy (17 and 18) substituents. Type II and type III inhibitors, did not exhibit
promising activities on the S. aureus gyrase and on topo IV, which could be explained by the lack
of the ortho substituents capable of forming favourable hydrophobic interactions or hydrogen
bonds with the enzyme.
Table 1. Inhibitory activities of type I compounds against DNA gyrase from E. coli.
Compd. R1 X R2 Y *
IC50 (nM)a or RA (%)b
E. coli gyrase
7a 4,5-diBr NHBoc H COOMe / 100%
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7b 3,4-diCl-5-Me H COOMe / 100%
7c 3,4-diCl-5-Me NHBoc CH3 COOMe L 83%
7d 3,4-diCl-5-Me NHBoc CH3 COOMe D 94%
8a 4,5-diBr NHBoc H COOH / 630 ± 100 nM
8b 3,4-diCl-5-Me NHBoc H COOH / 86 ± 18 nM
8c 3,4-diCl-5-Me NHBoc CH3 COOH L 80 ± 14 nM
8d 3,4-diCl-5-Me NHBoc CH3 COOH D 71 ± 2 nM
9a 4,5-diBr H COOH / 20 ± 3 nM
9b 3,4-diCl-5-Me H COOH / 17 ± 5 nM
9c 3,4-diCl-5-Me CH3 COOH L 9.9 ± 2.9 nM
9d 3,4-diCl-5-Me CH3 COOH D 6.9 ± 0.5 nM
10a 3,4-diCl-5-Me CH3 COOMe L 40 ± 22 nM
10b 3,4-diCl-5-Me CH3 COOMe D 48 ± 4 nM
15 3,4-diCl-5-Me H COOMe / 93%
16 3,4-diCl-5-Me H COOH / 92 ± 26 nM
17 3,4-diCl-5-Me H COOH / 31 ± 3 nM
18 3,4-diCl-5-Me H COOMe / 74 ± 12 nM
23 3,4-diCl-5-Me iPr CH3 COOMe D 87%
24 3,4-diCl-5-Me iPr CH3 COONHNH2 D 89%
25 3,4-diCl-5-Me iPr CH3 D 190 ± 30 nM
novobiocin 170 ± 20 nM
aConcentration of compound that inhibits the enzyme activity by 50%.bResidual activity of the enzyme at 1 µM of the
compound.
Table 2. Inhibitory activities of type II compounds against DNA gyrase from E. coli.
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Compd. R1 R2
IC50 (nM)a or RA (%)b
E. coli gyrase
27 3,4-diCl-5-Me 82%
29 3,4-diCl-5-Me 100%
33 3,4-diCl-5-Me 87%
34 3,4-diCl-5-Me 87%
39 3,4-diCl-5-Me 160 ± 10 nM
43a 4,5-diBr 960 ± 40 nM
43b 3,4-diCl-5-Me 410 ± 50 nM
46a 4,5-diBr 78%
46b 3,4-diCl-5-Me 7700 ± 900 nM
50 3,4-diCl-5-Me 77 ± 10 nM
novobiocin 170 ± 20 nM
aConcentration of compound that inhibits the enzyme activity by 50%.bResidual
activity of the enzyme at 1 µM of the compound.
Table 3. Inhibitory activities of type III compounds against DNA gyrase from E. coli.
Compd. Ar IC50 (nM)a or RA (%)b
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E. coli gyrase
56 53 ± 26 nM
57
1400 ± 200 nM
1000 ± 200 nMc
60 100%
61 98 ± 14 nM
novobiocin 170 ± 20 nM
aConcentration of compound that inhibits the enzyme activity by 50%.
bResidual activity of the enzyme at 1 µM of the compound. cResult
obtained with ATPase assay.
Table 4. Inhibitory activities of selected compounds against DNA gyrase from S. aureus and
against topoisomerase IV from E. coli and S. aureus.
Compd.
IC50 (nM)a or RA (%)b
S. aureus gyrase E. coli topo IV S. aureus topo IV
8b 1008 ± 300 nM 10000 ± 2000 nM 7400 ± 800 nM
8c 26% 88% 830 ± 120 nM
8d 68% 99% 79%
9a 67% 100% 100%
9b 960 ± 0.22 nM 7200 ± 6700 nM 3700 ± 2500 nM
9c 99 ± 11 nM 9100 ± 2200 nM 690 ± 30 nM
9d 31% 15000 ± 1000 nM 960 ± 40 nM
10a 1600 ± 300 nM 18000 ± 1000 nM 3700 ± 300 nM
10b 49% 89% 94%
17 290 ± 90 nM 16000 ± 2 nM 4300 ± 400 nM
18 950 ± 110 nM 90% 94%
25 59% 92% 90%
39 55% 98% 81%
50 47% 94% 85%
57 90% 92% 100%
novobiocin 41 ± 70 nM 11000 ± 2000 nM 27000 ± 7000 nM
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aConcentration of compound that inhibits the enzyme activity by 50%.bResidual activity
of the enzyme at 1 µM of the compound.
Antibacterial Activity. Antibacterial activities of the prepared inhibitors were evaluated against
the  ESKAPE  panel  (Enterococcus faecium ATCC 35667, Staphylococcus aureus ATCC
29213, Klebsiella pneumoniae ATCC 700603, Acinetobacter baumannii ATCC
19606, Pseudomonas aeruginosa ATCC27853, and Enterobacter aerogenes ATCC 13408). All
the compounds were additionally tested against wild-type E. coli ATCC 25922 and two E. coli
mutant strains, JD17464 and JW5503. E. coli JD17464 is an lpxC deletion mutant with impaired
outer membrane, while E. coli JW5503 is a tolC deletion mutant with defective efflux pump.
Sixteen compounds were also evaluated against E. faecalis (ATCC  29212).  The  results  are
presented in Table 1S and Table 2S (Supporting information) as growth inhibition (%). Minimum
inhibitory concentrations (MICs) were determined for compounds that inhibited one or more
bacterial strains by more than 60% (Tables 5 and 6).
Overall, compounds displayed much stronger inhibition of Gram-positive than Gram-negative
bacteria. Altogether five compounds (24, 25, 43b, 50 and 57) inhibited the growth of E. faecalis
by more than 85% at 50 µM concentration (Table 1S). Compound 25 displayed a better
antibacterial activity (MIC = 6.25 µM) than the corresponding hydrazide derivative 24 (MIC =
12.5 µM) (Table 5), probably because it is able to make stronger contacts with Arg136 through its
1,3,4-oxadiazol-2-thione ring on the right-hand side. Additionally, lower polarity of compound 25
compared to the more polar hydrazide 24 (see ChemGPS analysis below [31]) is believed to favour
the permeation into the bacterial cells. Four compounds (7c, 8c, 25 and 57) inhibited the growth of
E. faecium by more than 60% and two compounds (50 and 57) inhibited the growth of S. aureus
by more than 95% at 50 µM concentration (Table 1S). Of particular interest was the quinolone 57
that inhibited all the tested Gram-positive strains by more than 95%, with excellent MIC values of
0.78 µM against S. aureus, and of 1.56 µM against E. faecalis and E. faecium (Table 5). This result
is especially interesting, since this compound did not possess strong activity against DNA gyrase
(E. coli IC50 = 1.4 µM, S. aureus RA = 90%) or topoisomerase IV (E. coli RA = 92%, S. aureus
RA = 100%) enzymes, which could suggest a different mode of action for this compound.
Interestingly, the zwitterionic compounds 9b-d and 17,  which  were  the  most  potent  in  the
enzymatic assays, did not show good antibacterial activities. Probably these compounds have
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difficulties with passing through bacterial cell wall due to the presence of two charged functional
groups.
None of the compounds displayed significant inhibition of the wild-type E. coli but six of them
(10a, 10b, 18, 43b, 50 and 61) showed more than 80% inhibition of E. coli tolC deletion mutant
with defective efflux pump at 50 µM concentration (Table 2S), and for those compounds the MIC
values were between 3.13 and 25 µM (Table 6). These results indicate that some compounds are
subject to bacterial efflux, which is likely the main reason for their weaker activity against wild-
type Gram-negative bacteria. Among the compounds that were active against E. coli tolC deletion
mutant, three derivatives belonging to type I series (10a, 10b and 18) share similar structures, i.e.
a positively charged amino group-containing heterocycles on the central benzene ring and a methyl
carboxylate group on the right-hand side. This is in agreement with the recent reports, that the
overall positive charge of a molecule is an important factor to achieve higher level of accumulation
in E. coli [32]. Our results also confirm that the presence of a positively charged amino group alone
is not sufficient to obtain compounds with high accumulation in E. coli, but that other parameters
should be taken into account while designing antibacterials with Gram-negative activity, such as
high rigidity, low globularity and high amphiphilic moment [33]. In addition to type I compounds
10a, 10b and 18, other three compounds that significantly inhibited E. coli tolC deletion mutant
were the nitrile 43b (MIC = 12.5 µM), the 5-oxotetrazole derivative 50 (MIC = 3.13 µM) and the
indole derivative 61 (MIC = 12.5 µM) (Table 6).
Table 5. Minimum inhibitory concentrations (MICs) of compounds 7c, 8c, 24, 25, 43b, 50, and 57
against E. faecalis (ATCC 29212), E. faecium (ATCC 35667) and S. aureus (ATCC 29213).
Compd.
MIC (µM)a
E. faecalis (ATCC 29212) E. faecium (ATCC 35667) S. aureus (ATCC 29213)
7c n.d.b >125 n.d.
8c n.d. >125 n.d.
24 12.5 n.d. n.d.
25 6.25 >125 n.d.
43b 25 n.d. n.d.
50 12.5 n.d. 50
57 1.56 1.56 0.78
aMIC (minimum inhibitory concentration that inhibits the growth of bacteria by ≥ 90%) values against E. faecalis, E.
faecium and S. aureus. Ciprofloxacin was used as a positive control for E. faecalis and S. aureus at MIC of 3.02 and 1.51
µM, respectively. For E .faecium linezolid was used as positive control at MIC of 11.86 µM. bNot determined.
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Table 6. Minimum inhibitory concentrations (MICs) of compounds 10a, 10b, 18, 43b, 50 and 61
against E. coli (JW5503).
Compd.
MIC (µM)a
E. coli (JW5503)
10a 6.25
10b 6.25
18 25
43b 12.5
50 3.13
61 12.5
aMIC (minimum inhibitory concentration that
inhibits the growth of bacteria by ≥ 90%) values
against E. coli JW5503 (tolC deletion mutant).
Ciprofloxacin was used as a positive control at
a MIC of 0.015 µM.
Further Biological Evaluation of Compound 57. Overall, compound 57 was selected as the most
promising compound, since it displayed the lowest MIC values against Gram-positive bacteria.
Thus, for this compound we determined the MIC values against a panel of additional Gram-positive
and Gram-negative bacterial strains (Table 7). Compound 57 displayed promising MIC values of
0.72 µM against vancomycin-resistant E. faecium (VRE, ATCC 700221) and Streptococcus
pyogenes (ATCC 19653), and MIC values of 2.5 µM against methicillin-resistant S. aureus
(MRSA, ATCC 43300), ciprofloxacin non-susceptible and extremely drug resistant strain of S.
aureus (MRSA VISA, ATCC 700699), and S. aureus (ATCC 25923) strains. The activity against
methicillin-resistant S. aureus (MRSA, ATCC 43300) in the presence of 50% inactivated human
blood serum was also promising, with MIC value of 32 µM. Compound 57 was additionally
evaluated against the wild-type E. coli strains ATCC 25922 and MG1655 in the presence of efflux
pump substrate phenylalanine-arginine β-naphthylamide (PAβN), and the MIC values were 2.3 µM
and 2.5 µM, respectively. These results indicate that the inactivity against wild-type Gram-negative
organisms is probably associated with efflux. Also, MIC values against P. aeruginosa (ATCC
27853), K. pneumoniae (ATCC 10031), Shigella flexneri (HNCMB 20018) and Salmonella
enterica (LT2) were determined but were above 32 µM (Table 7).
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Given the quinolone substructure of compound 57, we decided to perform additional experiments
on E. coli and K. pneumoniae strains that possess mutations in the key amino acids of the GyrA
and GyrB binding sites, to investigate whether this compound binds preferably to the subunit A or
to the subunit B of the enzyme (Table 8). The results indicate that neither mutations at GyrA, nor
mutations at GyrB or ParC influence the MIC values of compound 57. This suggests a different
mode of action of compound 57.
To further investigate the mode of action of compound 57, we determined its inhibitory activity on
E. coli DNA gyrase using an ATP competitive assay (Table 3). This test measures the competitive
action of compounds against ATP and therefore provides experimental evidence that compounds
bind to the ATP binding pocket of the enzyme, located on the GyrB subunit. Since the activity of
compound 57,  determined  with  ATPase  assay  (IC50 =  1.0  µM),  was  similar  to  the  activity
determined with supercoiling assay (IC50 = 1.4 µM), its inhibition of DNA gyrase is most likely
due to binding to GyrB.
The possibility of compound 57 to bind to the fluoroquinolone binding site on the GyrA subunit
was additionally studied with molecular docking (Figure 2S, Supporting Information). The docking
pose of compound 57 in the S. aureus DNA gyrase (PDB entry: 2XCT [34]), superimposed with
the pose of ciprofloxacin, shows that compound 57 adopts a different conformation as
ciprofloxacin. In particular, compound 57 is not able to establish similar contacts with Mn2+, which
are crucial for the binding. The most likely reason is that the pyrrolamide portion of the compounds
is creating steric clashes, which prevent the compound to adopt the same orientation as
ciprofloxacin.
Table 7. Minimum inhibitory concentrations (MICs) of compound 57 against additional Gram-
positive and Gram-negative bacterial strains.
Compound 57 MIC (µM)a
Gram-positive bacteria
E. faecium (VRE, ATCC 700221) 0.72
Streptococcus pyogenes (ATCC 19653) 0.72
S. aureus (MRSA, ATCC 43300) 2.5
S. aureus (MRSA VISA ATCC 700699) 2.5
25
S. aureus (MRSA, ATCC 43300) + 50%
inactivated human blood serum
32
S. aureus (ATCC 25923) 2.5
Gram-negative bacteria
E. coli (ATCC 25922) >32
E. coli (ATCC 25922) + 50 µg/mL PAβN 2.3
E. coli (MG1655) + 50 µg/mL PAβN 2.5
P. aeruginosa (ATCC 27853) >32
K. pneumoniae (ATCC 10031) >32
S. flexneri (HNCMB 20018) >32
S. enterica (LT2) >32
aMIC (minimum inhibitory concentration that inhibits the growth of
bacteria by >90%) measurements were performed according to the
EUCAST guidelines in three independent measurements.
Table 8. Minimum inhibitory concentrations (MICs) of compound 57 against Gram-negative
bacterial  strains  with  mutated  amino  acids  in  the  GyrA or  GyrB active  sites  in  the  presence  of
phenylalanine-arginine β-naphthylamide (PAβN).
Strain
MIC (µM)a
Compd. 57 + 50 µg/ml PAβN
E. coli MG1655 (wild-type) 2.5
E. coli MG1655 GyrB R136C 2.5
E. coli MG1655 GyrA S83L 2.5
E. coli MG1655 GyrA S83L, D87N 2.5
E. coli MG1655 GyrA S83L, D87N; ParC S80I 2.5
E. coli MG1655 GyrA S83L, D87N; ParC S80I, E84G 2.5
K. pneumoniae (ATCC 10031) (wild-type) 1.2b
K. pneumoniae (ATCC 10031) GyrA S83F 1.2b
K. pneumoniae (ATCC 10031) GyrA S83Y 1.2b
K. pneumoniae (ATCC 10031) GyrA S83L 1.2b
K. pneumoniae (ATCC 10031) GyrA S83F, D87G 2.5b
K. pneumoniae (ATCC 10031) GyrA S83F, D87G; ParC S80I 1.2b
K. pneumoniae (ATCC 10031) GyrA S83F, D87G; ParC S80I, E84G 1.2b
aMIC (minimum inhibitory concentration that inhibits the growth of bacteria by > 90%) measurements
were performed according to the EUCAST guidelines in 3 independent measurements.  bMIC values were
determined in the presence of 10 µg/ml PAβN. Ciprofloxacin was used as a positive control. MIC values
of ciprofloxacin against E. coli MG1655 GyrB R136C and E. coli MG1655 GyrA S83L were 0.01 µM,
against E. coli MG1655 GyrA S83L, D87N was 0.19 µM, against E. coli MG1655 GyrA S83L, D87N;
ParC S80I was 8 µM and against E. coli MG1655 GyrA S83L, D87N; ParC S80I, E84G was >32 µM.
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Physicochemical Properties of the Tested Compounds. To investigate the physicochemical
space that our molecules are populating, and to link this information to their antibacterial activities,
we performed a chemographic mapping of all the synthesised compounds using the ChemGPS-
NPWeb tool  [35] (Figure 5). ChemGPS-NPWeb service is a useful tool that could provide valuable
information for designing compounds with broad-spectrum antibacterial activity [36]. For the
compounds that were prepared as L- and D-enantiomers, only the L-enantiomers (7c, 8c, 9c and
10a) were taken into consideration. For each compound, eight principal components (PCs) were
generated (PC1-8, Table 3S of Supporting information). Each PC describes different
physicochemical properties and, among those, the first three PCs (PC1-3) are the most significant.
PC1 accounts for size, shape and polarizability, PC2 comprises aromaticity and conjugation
properties, PC3 includes lipophilicity, polarity and H-bond formation capacity [37]. A description
for PC4, PC5, PC6, PC7 and PC8 is given in Table 3S of Supporting information. We plotted our
compounds in a 3D diagram, setting PC1, PC2 and PC3 as the x, y and z axes. In this study, the
value of PC1 correlates with the size of the compounds, PC2 correlates with the number of aromatic
rings and the degree of conjugation in the molecule, while the value of PC3 correlates with their
lipophilicity (cLogP). The chemographic plot shows that our compounds can be divided by PC3
into three groups: lipohphilic derivatives (red-yellow spheres), moderately lipophilic derivatives
(green spheres) and more polar compounds (blue spheres). Compounds 24, 25, 43b, 50 and 57 that
showed the most promising antibacterial activities against Gram-positive bacteria all possessed
moderately low values of PC3 (cLogP values were 1.07, 2.42, 1.34, 1.74 and 2.83, respectively)
and are represented by green-blue colour in the graph. Additionally, these compounds stay on the
lower side of PC1 (MW = 456, 497, 351, 353 and 408, respectively), indicating that they are small-
sized and less bulky than type I compounds 7a-7c, 8a-c, 15 and 16 (MW = 658, 583, 597, 644,
569, 583, 569 and 555, respectively). The zwitterionic compounds 9b, 9c and 17, which were the
most  potent  in  the  enzymatic  assays,  show relatively  low lipophilicity  (cLogP =  1.01,  1.31  and
0.89, respectively) and are medium sized (medium value of PC1, MW = 490-510). Most probable
reason for their inactivity in bacteria is the simultaneous presence of two charged groups, which
makes their entry into bacterial cell more problematic.
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Figure 5. Chemographic plot of the synthesised compounds. In the colour map displayed on the
right, the red-yellow band represents the lipophilic region, the green band represents the moderately
lipophilic region and the blue band represents the more polar region. The values of cLogP described
in the text were calculated by ChemOffice 2016 [38]. The graph was prepared by Teraplot [39].
We performed a computational study on Lipinski's rule of five parameters for the most promising
compounds 24, 25, 43b, 50 and 57. The study was carried out using SwissADME free tool [40].
Lipinski’s parameters (molecular weight, MLOGP [41], number of H-bond donors and H-bond
acceptors) and calculated water solubility (LogS [42]) are reported in Table 9. All selected
compounds complied to Lipinski’s rules.
Table 9. Lipinski’s parameters (molecular weight, MLOGP, number of H-bond donors and H-bond
acceptors) and predicted water solubility (LogS) of compounds 24, 25, 43b, 50 and 57.
Compd. MW (g/mol) MLOGP H-bond acceptor H-bond donor LogS
24 456.32 1.13 5 5 -3.91
25 498.38 1.57 5 4 -5.33
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43b 351.19 1.08 3 3 -3.61
50 353.16 2.41 4 3 -4.32
57 408.24 1.74 4 3 -4.95
In vitro Cytotoxicity Measurements. Cytotoxicity of compounds 17, 25 and 56, representatives
of type I, type II and type III structures, was determined in a MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay on human HepG2 cells
(hepatocellular carcinoma cells) and on HUVEC cells (human umbilical vein endothelial cells).
The decrease in cell proliferation after the treatment with compounds was compared to the decrease
of etoposide-treated cells at 50 µM concentration. None of the compounds showed significant
cytotoxic activity against HepG2 cells and HUVEC cells at 50 µM concentration (Table 10).
Table 10. Cytotoxic activity of compounds 17, 25 and 56 against HepG2 and HUVEC cell lines.
Compd.
% viabilitya
HepG2 cell line HUVEC cell line
17 46% 130%
25 80% 85%
56 90% 88%
Etoposide IC50 = 20 ± 1.6 µM IC50 = 5.2 ± 2.8 µM
aDetermined in MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) assay
CONCLUSION
Given the rising bacterial resistance to existing antibacterials, there is a constant need for new drugs
acting through the so-far less exploited mechanisms. Thus, we have designed and prepared a series
of new N-phenylpyrrolamides as DNA gyrase and topoisomerase IV inhibitors interacting with the
ATP binding site.  The most potent DNA gyrase and topo IV inhibitors of the series, 9c and 9d,
contained a carboxylic moiety on the right-hand side of the molecules and a piperidin-4-yloxy
substituent on the central benzene ring, and displayed excellent IC50 values of 9.9 nM and 6.9 nM
against E. coli DNA gyrase, respectively. The IC50 value of 9c against S. aureus topo IV was 0.69
µM. Several compounds displayed antibacterial activity against Gram-positive strains. The most
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potent was quinolone derivative 57 that inhibited the growth of several bacteria with excellent MIC
values: E. faecalis (MIC = 1.56 µM), E. faecium (MIC = 1.56 µM), S. aureus (MIC = 0.78 µM),
S. pyogenes (MIC = 0.72 µM), MRSA (MIC = 2.5 µM) and extremely drug resistant strain of S.
aureus (MRSA VISA) (MIC = 2.5 µM). Compound 57 displayed the MIC value of 32 µM against
MRSA in the presence of inactivated human blood serum, and thus represents a promising scaffold
for the preparation of further optimized compounds. Since the on-target activity of compound 57
(E. coli DNA gyrase IC50 = 1.4 µM) cannot fully explain its good antibacterial activity, further
studies are needed to confirm its mode of action. Although none of the compounds possessed
significant activities against wild-type Gram-negative bacteria, some of the compounds were active
against the E. coli mutant strain with defective efflux pump, e.g. compound 50 with MIC of 3.13
µM, indicating that efflux mechanisms are a considerable factor counteracting antibacterial activity
of our compounds. To accumulate inside Gram-negative bacteria, small molecules thus need to
penetrate into bacteria faster than they are pumped out. To achieve this, the physicochemical
properties of compounds need to be carefully optimised. Chemographic mapping of our
compounds presented herein provides useful information in the search of a more optimal
physicochemical space that would result in the discovery of compounds with broad-spectrum
antibacterial activities.
EXPERIMENTAL SECTION
Determination of Inhibitory Activities on E. coli and S. aureus DNA Gyrase and
Topoisomerase IV. The assay for the determination of IC50 values was performed according to
previously reported procedures [13]. An ATPase assay on E. coli DNA gyrase for compound 57
was performed by Inspiralis according to reported procedure [17].
Determination of Antibacterial Activity.
Clinical microbiology control strains of A. baumannii (ATCC19606), E. aerogenes (ATCC13408),
E. faecalis (ATCC 29212), E. faecium (ATCC 35667), E. faecium (ATCC 700221), E. coli (ATCC
25922), K. pnemoniae (ATCC 700603 and ATCC 10031), P. aeruginosa (ATCC 27853), and S.
aureus (ATCC 25913) and S. aureus (MRSA VISA ATCC 700699) were obtained from
Microbiologics Inc. (St. Cloud, MN). E. coli MG1655 originated from the laboratory collection of
Dr.  Csaba  Pál.  GyrA,  GyrB,  and  ParC  mutant  strains  of E. coli MG1655 and K. pneumoniae
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ATCC10031 were constructed using pORTMAGE recombineering technology [43]. S. flexneri
(HNCMB 20018), S. aureus (MRSA, ATCC 43300), S. aureus (ATCC 25923) and Streptococcus
pyogenes (ATCC 19653) were obtained from the University of Szeged (Hungary). S. enterica
(LT2) was originated from the laboratory collection of Donald L. Court (USA). Single-gene knock-
out mutant strains of E. coli JW5503 (tolC knock-out) and JD17464 (lpxC knock-out) were
obtained from the NBRP E.coli collection at the National Institute of Genetics (NIG, Japan [44]).
To determine antibacterial activity, broth microdilution assays in 96-well plates were carried out
by following the Clinical Laboratory Standard Institute guidelines the Clinical Laboratory Standard
Institute guidelines [45]. For selected compounds, MIC values were determined by dose–response
experiments (reported values are from at least two independent experiments, each with three
replicates per concentration). In the experiments with the efflux inhibitor, the assay media was
supplemented with PAβN (50 µg/mL PAβN, Sigma-Aldrich, Switzerland). Human blood serum
was purchased from Sigma-Aldrich.
In vitro cytotoxicity measurements.
Cytotoxicity of compounds 17, 25 and 56 was determined in MTS (3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay [46] with a few
modifications. HepG2 (ATCC) and HUVEC (ATCC) cells were cultured in Eagle's MEM medium
supplemented with L-glutamine (2 mM), penicillin/streptomycin (100 UI/mL/100 µg/mL), and
10% FBS. The cells were incubated in a humidified atmosphere with 5% CO2 at 37 °C.
The cells were seeded in 96-well plates at densities 2000 cells per well in 100 µL of growth medium
and incubated for 24 h to attach onto the wells. 50 µL of compounds at 50 µM concentration in
DMSO (0.5% final concentration) were added and incubated for 72 h. After 72 h 10 µL of
CellTiter96® Aqueous One Solution Reagent, (Promega) [47] was added to determine the number
of viable cells. The plates were incubated for another 3 h and absorbance (490 nm) was read with
a BioTek's Synergy H4 microplate reader. Etoposide [IC50 =  20.1  µM (Ref.  [48]:  30.2  µM) for
HepG2 and IC50 = 5.21 µM (Ref. [49]: 1.25 µM) for HUVEC] at 50 µM concentration was used
as a positive control and 0.5% DMSO as a vehicle control. To determine cell viability, results from
the wells that contained test compound-treated cells were compared to those with cells incubated
in 0.5% DMSO. Independent experiments were run in triplicate and repeated two times. Statistical
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significance (p < 0.05) was calculated with two-tailed Welch's t-test between treated groups and
DMSO.
Molecular Modelling.
Protein and ligand preparation and ligand docking were performed using GOLD Suite v5.4 [50]
according to previously reported procedures [14]. Detailed procedures can be found in Supporting
Informantion.
Chemistry. Chemicals were obtained from Acros Organics (Geel, Belgium), Sigma-Aldrich (St.
Louis, MO, USA) and Apollo Scientific (Stockport, UK) and used without further purification.
Analytical TLC was performed on silica gel Merck 60 F254 plates (0.25 mm), using visualization
with UV light and spray reagents. Column chromatography was carried out on silica gel 60 (particle
size 240–400 mesh). HPLC analyses were performed on an Agilent Technologies 1100 instrument
(Agilent Technologies, Santa Clara, CA, USA) with a G1365B UV-Vis detector, a G1316A
thermostat,  a  G1313A autosampler,  and  a  ChemStation  Data  System or  on  a  Thermo Scientific
Dionex Ultimate 3000 Binary Rapid Separation LC System (Thermo Fisher Scientific, Waltham,
MA, USA) with an autosampler, a binary pump system, a photodiode array detector, a thermostated
column compartment, and a Chromeleon Chromatography Data System. The columns used were
Agilent Eclipse C18 column (5 μm, 4.6 × 150 mm) or Phenomenex Luna C18 column (5 μm, 4.6
× 250 mm), with a flow rate of 1.0 mL/min. The eluent consisted of trifluoroacetic acid (0.1% in
water) or 20 mM phosphate buffer (pH 6.8) as solvent A and acetonitrile as solvent B. Melting
points were determined on a Reichert hot stage microscope and are uncorrected. 1H and 13C NMR
spectra were recorded at 400 and 100 MHz, respectively, on a Bruker AVANCE III 400
spectrometer  (Bruker  Corporation,  Billerica,  MA,  USA)  in  DMSO-d6, CDCl3 or acetone–d6
solutions, with TMS as the internal standard. IR spectra were recorded on a Thermo Nicolet Nexus
470 ESP FT-IR spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). Mass spectra were
obtained using a Q-TOF Premier mass spectrometer (Micromass, Waters, Manchester, UK) or
ADVION expression CMSL mass spectrometer (Advion Inc., Ithaca, USA). Optical rotations were
measured  on  a  Perkin-Elmer  241  MC polarimeter.  The  reported  values  for  specific  rotation  are
32
average values of 10 successive measurements using an integration time of 5 s. The purity of the
tested compounds was ≥ 95% as established by HPLC.
Synthetic Procedures.
General procedure A. Synthesis of Compounds 3, 11 and 19 (with 3 as an Example). To a stirred
solution of compound 2 (3.08 g, 15.7 mmol) and triphenylphosphine (5.50 g, 21.0 mmol) in
anhydrous tetrahydrofuran (200 mL) 1-Boc-4-hydroxypiperidine (4.0 g, 19.9 mmol) was added
and the mixture was stirred at rt for 10 min. Diisopropyl azodicarboxylate (DIAD, 3.91 mL, 19.87
mmol) was added dropwise and the mixture was stirred at rt for 15 h under argon atmosphere. The
solvent was evaporated under reduced pressure and the crude product was purified with flash
column chromatography using ethyl acetate/petroleum ether (1/2) as an eluent to give 3 (3.2 g) as
yellow solid.
tert-Butyl 4-(5-(methoxycarbonyl)-2-nitrophenoxy)piperidine-1-carboxylate (3). Yellow
solid; yield 54% (3.2 g); mp 66-68 °C; IR (ATR) ν = 2974, 1726, 1689, 1603, 1525, 1485, 1408,
1364, 1300, 1279, 1235, 1165, 1030, 749, 671 cm-1. 1H NMR (400 MHz, CDCl3): δ = 1.49 (s, 9H,
3 × CH3), 1.84-1.99 (m, 4H, 4×(CH)CH-O-Ar), 3.53-3.60 (m, 4H, 4×CHNBoc), 3.98 (s, 3H,
COOCH3), 4.78-4.83 (m, 1H, CH-O-Ar), 7.70 (dd,1H, 3J = 8.4 Hz, 4J = 1.6 Hz, Ar-H-4), 7.75 (d,
4J = 1.6 Hz, 1H, Ar-H-6), 7.83 (d, 1H, 3J = 8.4 Hz, Ar-H-3). 13C NMR (100 MHz, CDCl3) δ 28.44
(3  ×  CH3), 29.99, 39.89, 52.92, 74.00, 79.78, 116.75, 121.62, 125.48, 134.66, 143.63, 150.11,
154.73, 165.23 (COOCH3). MS (ESI) m/z = 331.37 ([M+H]+), HRMS for C18H25N2O7: calculated
381.1656, found 381.1662.
General procedure B. Synthesis of Compounds 4, 12, 20 (with 4 as an Example). To the solution
of compound 3 (2.90 g, 7.63 mmol) in methanol (50 mL) 1 M NaOH (30.4 mL, 30.4 mmol) was
added. The mixture was stirred at rt for 15 h. The solvent was removed under reduced pressure,
EtOAc (20 mL) and 1M HCl (20 mL) were added to the residue. The organic phase was washed
with brine (2 × 20 mL), dried over Na2SO4, filtered and the solvent removed under reduced pressure
to afford 4 (2.60 g) as white solid.
3-((1-(tert-Butoxycarbonyl)piperidin-4-yl)oxy)-4-nitrobenzoic acid (4). White solid; yield
93% (2.60 g); mp 158-161 °C; IR (ATR) ν = 2963, 2866, 1720, 1689, 1523, 1406, 1298, 1237,
1223, 1165, 1120, 1033, 841, 772, 746 cm-1. 1H NMR (400 MHz, CDCl3): δ = 1.50 (s,  9H, 3 ×
CH3), 1.87-1.99 (m, 4H, 4×(CH)CH-O-Ar), 3.53-3.63 (m, 4H, 4×CHNBoc), 4.64 (br s, 1H,
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COOH), 4.80-4.85 (m, 1H, CH-O-Ar), 7.77-7.81 (m, 2H, Ar-H-2,6), 7.84-7.86 (d, 1H, 3J = 8.3 Hz
Ar-H-5). 13C NMR (100 MHz, CDCl3)  δ 28.45  (3  ×  CH3), 29.95, 39.91, 73.99, 80.11, 117.12,
122.26, 125.55, 133.79, 144.12, 150.09, 154.91, 168.62 (COOH). MS (ESI) m/z = 365.1 ([M-H]-),
HRMS for C17H21N2O7: calculated 365.1342, found 365.1349.
General procedure C. Synthesis of Compounds 5a-c, 13, 21, 41 and 44 (with 5a as an Example).
To the suspension of 4 (0.872 g, 2.38 mmol) and TBTU (0.993 g, 3.09 mmol) in anhydrous DMF
(48 mL), N-methylmorpholine (1.42 mL, 12.99 mmol) was added. The reaction mixture was stirred
at rt for 30 min upon which a clear solution formed. Glycine methyl ester hydrochloride (0.328 g,
2.62 mmol) was added and the mixture was stirred at 60 °C for 12 h. The solvent was removed
under reduced pressure and the residue was dissolved in ethyl acetate (30 mL) and NaHCO3
solution (30 mL). The organic phase was dried over Na2SO4, filtered and the solvent evaporated
under reduced pressure. The residue was purified with column chromatography using ethyl
acetate/petroleum ether (4/1) as an eluent to give 5a (0.770 g) as a pale yellow solid.
tert-Butyl 4-(5-((2-methoxy-2-oxoethyl)carbamoyl)-2-nitrophenoxy)piperidine-1-
carboxylate (5a). Pale yellow solid; yield 74% (0.770 g); mp 115-116 °C; IR (ATR) ν = 3373,
2964, 2867, 1752, 1663, 1523, 1479, 1412, 1163, 1032, 960, 842, 747 cm-1. 1H NMR (400 MHz,
CDCl3): δ =  1.49  (s,  9H,  3  ×  CH3), 1.83-1.99 (m, 4H, 4×(CH)CH-O-Ar), 3.52-3.62 (m, 4H,
4×CHNBoc), 3.85 (s, 3H, COOCH3), 4.27 (d, 2H, 3J = 5.0 Hz, NHCH2COOCH3), 4.79-4.84 (m,
1H, CH-O-Ar), 6.74 (t, 1H, 3J = 5.0 Hz, NHCH2COOCH3), 7.35 (dd, 1H, 3J = 8.4 Hz, 4J = 1.6 Hz,
Ar-H-4), 7.64 (d, 1H, 4J = 1.6 Hz, Ar-H-6), 7.87 (d, 1H, 3J = 8.4 Hz, Ar-H-3). 13C NMR (100 MHz,
CDCl3) δ 28.44 (3 × CH3), 30.04, 39.94, 41.89, 52.76, 74.09, 79.78, 115.47, 117.90, 125.86,
138.50, 142.72, 150.73, 154.72, 165.36, 170.17 (COOCH3). MS (ESI) m/z = 463.2 ([M-H]-),
HRMS for C20H26N3O8: calculated 436.1730, found 436.1720.
General procedure D. Synthesis of Compounds 6a-c, 14, 22, 32, 38, 42 and 49 (with 6a as an
Example). Compound 5a (0.750 g, 1.71 mmol) was dissolved in MeOH (20 mL) and the mixture
was stirred for 30 min under argon atmosphere. Pd/C (0.075 g) was added and the reaction mixture
was stirred under hydrogen atmosphere for 5 h. The catalyst was filtered off and the solvent
removed under reduced pressure to obtain 6a (0.686 g) as light brown oil.
tert-Butyl 4-(2-amino-5-((2-methoxy-2-oxoethyl)carbamoyl)phenoxy)piperidine-1-
carboxylate (6a). Light brown oil; yield 98% (0.686 g); IR (ATR) ν = 3350, 2962, 1750, 1681,
1611, 1524, 1506, 1428, 1365, 1223, 1164, 1030, 762 cm-1. 1H NMR (400 MHz, CDCl3) δ = 1.49
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(s, 9H, 3 × CH3), 1.72-1.80 (m, 2H, 2×(CH)CH-O-Ar), 1.96-2.04 (m, 2H, 2×(CH)CH-O-Ar), 3.27-
3.34 (m, 2H, 2×CHNBoc), 3.72-3.80 (m, 2H, 2×CHNBoc), 3.82 (s, 3H, COOCH3), 4.16 (s, 2H,
NH2), 4.24 (d, 2H, 3J = 5.0 Hz, NHCH2COOCH3), 4.55-4.63 (m, 1H, CH-O-Ar), 6.52 (t, 1H, 3J =
5.0 Hz, NHCH2COOCH3), 6.71 (d, 1H, 3J = 8.0 Hz, Ar-H-3), 7.22 (dd, 1H, 3J = 8.0 Hz, 4J = 1.8
Hz, Ar-H-4), 7.42 (d, 1H, 4J = 1.8 Hz, Ar-H-6). 13C NMR (100 MHz, DMSO-d6) δ = 28.05 (3 ×
CH3), 30.27, 41.12, 51.60, 54.89, 72.47, 78.64, 112.76, 113.32, 120.56, 121.81, 142.32, 142.79,
153.89, 166.45, 170.82 (COOCH3). MS (ESI) m/z = 408.2 ([M+H]+),  HRMS  for  C20H30N3O6:
calculated 408.2127, found 408.2135.
General procedure E. Synthesis of Compounds 7a-d, 15, 23, 43a-b, 46a-b, 50, 56 and 60 (with
7a as an Example). To a solution of 4,5-dibromo-1H-pyrrole-2-carboxylic acid (200 mg, 0.743
mmol) in anhydrous dichloromethane (5 mL), oxalyl chloride (0.317 mL, 3.70 mmol) was added
dropwise and the solution stirred at rt for 15 h under argon atmosphere. The solvent was evaporated
under reduced pressure, fresh anhydrous dichloromethane (2 mL), 6a (0.251 g, 0.616 mmol) and
pyridine (2 mL) were added and the reaction mixture stirred under argon atmosphere at rt for 15 h.
Solvent was removed under reduced pressure, the residue dissolved in ethyl acetate (15 mL) and
washed with HCl 1M solution (15 mL) and brine (2 × 15 mL). The organic phase was dried over
Na2SO4, filtered and the solvent removed under reduced pressure. The solid was then washed with
diethyl ether (2 × 5 mL) to afford 7a (0.153 g) as light brown solid.
tert-Butyl 4-(2-(4,5-dibromo-1H-pyrrole-2-carboxamido)-5-((2-methoxy-2-
oxoethyl)carbamoyl)phenoxy)piperidine-1-carboxylate (7a). Light brown solid; yield 38%
(0.153 g); mp 204-205 °C; IR (ATR) ν = 3402, 3357, 3296, 2955, 1724, 1693, 1642, 1656, 1513,
1414, 1367, 1316, 1239, 1169, 1127, 1050, 758, 651 cm-1. 1H NMR (400 MHz, DMSO-d6) δ =
1.40 (s, 9H, 3 × CH3), 1.64-1.73 (m, 2H, 2×(CH)CH-O-Ar), 1.86-1.95 (m, 2H, 2×(CH)CH-O-Ar),
3.18-3.29 (m, 2H, 2×CHNBoc), 3.60-3.66 (m, 5H, 2×CHNBoc, COOCH3), 4.02 (d, 2H, 3J = 5.8
Hz, NHCH2COOCH3), 4.65-4.70 (m, 1H, CH-O-Ar), 7.18 (d, 1H, 4J = 2.5 Hz,  Pyrrole-CH), 7.22
(dd, 1H, 3J = 8.4 Hz, 4J = 1.7 Hz, Ar-H-4), 7.59 (d, 1H, 4J = 1.7 Hz, Ar-H-6), 7.90 (d, 1H, 3J = 8.4
Hz, Ar-H-3), 8.92 (t, 1H, 3J = 5.8 Hz, NHCH2COOCH3), 9.15 (s, 1H, NHAr), 13.01 (d, 1H, 4J =
2.5 Hz,  Pyrrole-NH). 13C NMR (100 MHz, DMSO-d6)  δ 28.04 (3 × CH3), 30.03, 41.24, 51.74,
73.31, 78.71, 98.39, 106.33, 112.99, 113.90, 120.09, 123.27, 127.56, 130.17, 130.70, 148.08,
153.86, 157.13, 165.93, 170.45, one aliphatic signal is not seen. MS (ESI) m/z = 655.0 ([M-H]-),
HRMS for C25H29Br2N4O7: calculated 655.0400, found 655.0403; HPLC: Phenomenex Luna C18
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column (5 µm, 4.6 × 250 mm); mobile phase: 10-70% of acetonitrile in phosphate buffer (pH =
6.8) in 15 min, 70% acetonitrile to 25 min; flow rate 1.0 mL/min; injection volume: 10 μL; tR:
21.273 min (96.8% at 280 nm).
tert-Butyl 4-(2-(3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamido)-5-((2-methoxy-2-
oxoethyl)carbamoyl)phenoxy)piperidine-1-carboxylate (7b). Synthesized according to General
procedure E from 6a (397 mg, 0.975 mmol), with 3,4-dichloro-5-methyl-1H-pyrrole-2-carboxylic
acid (0.228 g, 1.17 mmol) instead of 4,5-dibromo-1H-pyrrole-2-carboxylic acid as a reagent.
During extraction a precipitate formed which was filtered off. The mother liquor was extracted and
the filtered part of the compound was combined with the part after extraction. To the crude product
diethyl ether (15 mL) was added, the obtained suspension was sonicated, filtered, washed with
diethyl ether (2 × 5 mL) and dried to afford 7b (0.200 g) as white solid. Yield 31% (0.200 g); mp
213-215 °C; IR (ATR) ν = 3410, 3359, 3303, 2956, 2850, 1726, 1695, 1642, 1511, 1413, 1367,
1238, 1209, 1170, 1125, 1050, 758, 651 cm-1. 1H NMR (400 MHz, DMSO-d6) δ = 1.42 (s, 9H, 3 ×
CH3), 1.51-1.62 (m, 2H, 2×(CH)CH-O-Ar), 2.01-2.09 (m, 2H, 2×(CH)CH-O-Ar), 2.24 (s, 3H,
Pyrrole-CH3), 3.04-3.17 (m, 2H, 2×CHNBoc), 3.67 (s, 3H, COOCH3), 3.78-3.86 (m, 2H,
2×CHNBoc), 4.03 (d, 2H, 3J = 5.8 Hz, NHCH2COOCH3), 4.74-4.81 (m, 1H, CH-O-Ar), 7.56 (dd,
1H, 3J = 8.6 Hz, 4J = 1.8 Hz, Ar-H-4), 7.65 (d, 1H, 4J = 1.8 Hz, Ar-H-6), 8.47 (d, 1H, 3J = 8.6 Hz,
Ar-H-3), 8.93 (t, 1H, 3J = 5.8 Hz, NHCH2COOCH3), 9.16 (s, 1H, NHAr), 12.46 (s, 1H, Pyrrole-
NH). 13C NMR (100 MHz, DMSO-d6) δ = 10.75 (Pyrrole-CH3), 28.02 (3 × CH3), 30.63, 41.25,
51.73, 74.10, 78.85, 108.59, 109.75, 111.83, 118.49, 118.69, 120.62, 128.53, 129.79, 131.21,
144.92, 153.93, 156.33, 165.84, 170.48, one aliphatic signal is not seen. MS (ESI) m/z = 581.1
([M-H]-), HRMS for C26H31Cl2N4O7: calculated 581.1564, found 581.1570. HPLC: Phenomenex
Luna C18 column (5 µm, 4.6 × 250 mm); mobile phase: 10-70% of acetonitrile in phosphate buffer
(pH = 6.8) in 15 min, 70% acetonitrile to 25 min; flow rate 1.0 mL/min; injection volume: 10 μL;
tR: 21.223 min (96.2% at 280 nm).
(S)-tert-Butyl 4-(2-(3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamido)-5-((1-methoxy-1-
oxopropan-2-yl)carbamoyl)phenoxy)piperidine-1-carboxylate (7c). Synthesized according to
General procedure E from 6b (179 mg, 0.425 mmol), with 3,4-dichloro-5-methyl-1H-pyrrole-2-
carboxylic acid (0.099 g, 0.51 mmol) instead of 4,5-dibromo-1H-pyrrole-2-carboxylic acid as a
reagent. During extraction a precipitate formed which was filtered off. The mother liquor was
extracted and the filtered part of the compound was combined with the part after extraction. To the
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crude product diethyl ether (15 mL) was added, the obtained suspension was sonicated, filtered,
washed with diethyl ether (2 × 5 mL) and dried to afford 7c (0.150 g) as light brown solid. Yield
59% (0.150 g); mp 181-185 °C; [α]D25 +10.8 (c 0.167, MeOH). IR (ATR) ν = 3373, 2935, 1739,
1682, 1643, 1659, 1596, 1510, 1418, 1239, 1163, 1134, 1032, 977, 868, 757 cm-1. 1H NMR (400
MHz, DMSO-d6) δ = 1.41-1.44 (m, 12H, 3 × CH3, CH3CH), 1.51-1.63 (m, 2H, 2×(CH)CH-O-Ar),
1.99-2.09 (m, 2H, 2×(CH)CH-O-Ar), 2.24 (s, 3H, Pyrrole-CH3), 3.06-3.19 (m, 2H, 2×CHNBoc),
3.66 (s, 3H, COOCH3), 3.76-3.84 (m, 2H, 2×CHNBoc), 4.44-4.51 (m, 1H, CH-O-Ar), 4.76-4.82
(m, 1H, NHCHCOOCH3), 7.59 (dd, 1H, 3J = 8.6 Hz, 4J = 1.7 Hz, Ar-H-4), 7.64 (d, 1H, 4J = 1.7
Hz, Ar-H-6), 8.46 (d, 1H, 3J = 8.6 Hz, Ar-H-3), 8.75 (d, 1H, 3J = 6.9 Hz, NHCHCOOCH3), 9.16
(s, 1H, NHAr), 12.45 (s, 1H, Pyrrole-NH). 13C NMR (100 MHz, DMSO-d6) δ = 10.76 (Pyrrole-
CH3), 16.76 (CH3CH), 28.01 (3 × CH3), 30.57, 48.34, 51.88 (OCH3), 74.11, 78.85, 108.59, 109.74,
112.22, 118.42, 118.69, 120.81, 128.60, 129.79, 131.27, 144.89, 153.95, 156.33, 165.46, 173.26,
one  aliphatic  signal  is  not  seen.  MS  (ESI) m/z = 595.2 ([M-H]-),  HRMS  for  C27H33Cl2N4O7:
calculated 595.1721, found 595.1726. HPLC: Phenomenex Luna C18 column (5 µm, 4.6 × 250
mm); mobile phase: 10-70% of acetonitrile in phosphate buffer (pH = 6.8) in 15 min, 70%
acetonitrile to 25 min; flow rate 1.0 mL/min; injection volume: 10 μL; tR: 22.793 min (97.9% at
220 nm).
(R)-tert-Butyl 4-(2-(3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamido)-5-((1-methoxy-1-
oxopropan-2-yl)carbamoyl)phenoxy)piperidine-1-carboxylate (7d). Synthesized according to
General procedure E from 6c (397 mg, 0.942 mmol), with 3,4-dichloro-5-methyl-1H-pyrrole-2-
carboxylic acid (0.220 g, 1.13 mmol) instead of 4,5-dibromo-1H-pyrrole-2-carboxylic acid as a
reagent. During extraction a precipitate formed which was filtered off. The mother liquor was
extracted and the filtered part of the compound was combined with the part after extraction. To the
crude product diethyl ether (15 mL) was added, the obtained suspension was sonicated, filtered,
washed with diethyl ether (2 × 5 mL) and dried to afford 7d (0.350 g) as light brown solid. Yield
60% (0.350 g); mp 181-185 °C; [α]D25 -11.7 (c 0.213, MeOH). IR (ATR) ν = 3369, 2974, 1741,
1683, 1643, 1595, 1510, 1347, 1240, 1032, 868, 758 cm-1. 1H NMR (400 MHz, DMSO-d6) δ =
1.41-1.44 (m, 12H, 3 × CH3, CH3CH), 1.51-1.63 (m, 2H, 2×(CH)CH-O-Ar), 1.99-2.09 (m, 2H,
2×(CH)CH-O-Ar), 2.24 (s, 3H, Pyrrole-CH3), 3.06-3.19 (m, 2H, 2×CHNBoc), 3.66 (s, 3H,
COOCH3), 3.76-3.84 (m, 2H, 2×CHNBoc), 4.44-4.51 (m, 1H, CH-O-Ar), 4.76-4.82 (m, 1H,
NHCHCOOCH3), 7.59 (dd, 1H, 3J = 8.6 Hz, 4J = 1.7 Hz, Ar-H-4), 7.64 (d, 1H, 4J = 1.7 Hz, Ar-H-
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6), 8.46 (d, 1H, 3J =  8.6  Hz,  Ar-H-3),  8.75  (d,  1H, 3J = 6.9 Hz, NHCHCOOCH3), 9.16 (s, 1H,
NHAr), 12.45 (s, 1H, Pyrrole-NH). 13C  NMR  (100  MHz,  DMSO-d6) δ = 10.76 (Pyrrole-CH3),
16.76 (CH3), 28.01 (3 × CH3), 30.57, 48.34, 51.88 (OCH3), 74.11, 78.85, 108.59, 109.74, 112.22,
118.42, 118.69, 120.81, 128.60, 129.79, 131.27, 144.89, 153.95, 156.33, 165.46, 173.26, one
aliphatic signal is not seen. MS (ESI) m/z = 595.2 ([M-H]-), HRMS for C27H33Cl2N4O7: calculated
595.1721, found 595.1726. HPLC: Phenomenex Luna C18 column (5 µm, 4.6 × 250 mm); mobile
phase: 10-70% of acetonitrile in phosphate buffer (pH = 6.8) in 15 min, 70% acetonitrile to 25 min;
flow rate 1.0 mL/min; injection volume: 10 μL; tR: 22.800 min (96.7% at 220 nm).
(S)-tert-Butyl 3-(2-(3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamido)-5-((2-methoxy-2-
oxoethyl)carbamoyl)phenoxy)pyrrolidine-1-carboxylate (15). Synthesized according to
General procedure E from 14 (543 mg, 1.38 mmol), with 3,4-dichloro-5-methyl-1H-pyrrole-2-
carboxylic acid (0.320 g, 1.65 mmol) instead of 4,5-dibromo-1H-pyrrole-2-carboxylic acid as a
reagent. During extraction a precipitate formed which was filtered off. The mother liquor was
extracted and the filtered part of the compound was combined with the part obtained after
extraction. To the crude product diethyl ether (15 mL) was added, the obtained suspension was
sonicated, filtered, washed with diethyl ether (2 × 5 mL) and dried to afford 15 (0.440 g) as light
brown solid. Yield 61% (0.440 g); mp 218-220 °C; [α]D25 +57.7 (c 0.137, MeOH). IR (ATR) ν =
3369, 3233, 2972, 1750, 1688, 1645, 1598, 1516, 1494, 1411, 1364, 1256, 1177, 1118, 882, 757
cm-1. 1H NMR (400 MHz, DMSO-d6) δ = 1.43 (d, 9H, 3J = 6.6 Hz, 3 × CH3), 2.08-2.20 (m, 2H,
2×CH), 2.23 (s, 3H, Pyrrole-CH3), 3.44-3.67 (m, 7H, 4×CH, COOCH3), 4.03 (d, 2H, 3J = 5.8 Hz,
NHCH2COOCH3), 5.24-5.28 (m, 1H, CH-O-Ar), 7.56-7.61 (m, 2H, Ar-H-4,6), 8.48-8.51 (m, 1H,
Ar-H-3), 8.98 (t, 1H, 3J = 5.8 Hz, NHCH2COOCH3), 9.17 (d,1H, 3J = 7.0 HzNHAr), 12.44 (s, 1H,
Pyrrole-NH). 13C NMR (100 MHz, DMSO-d6) δ = 10.75 (Pyrrole-CH3), 28.09 (3 × CH3), 29.49
and 30.40 (one split signal), 41.23, 43.55 and 43.71 (one split signal), 51.62 and 51.89 (one split
signal), 51.74 (COOCH3), 76.59 and 77.53 (one split signal), 78.57 and 78.65 (one split signal),
108.64, 109.93, 110.58 and 110.74 (one split signal), 118.18, 118.58, 120.61 and 120.67 (one split
signal), 128.27, 129.86, 130.95, 144.65, 153.34 and 153.52 (one split signal), 156.29, 165.78,
170.48. MS (ESI) m/z = 567.1 ([M-H]-),  HRMS for C25H29Cl2N4O7: calculated 567.1410, found
567.1413. HPLC: Phenomenex Luna C18 column (5 µm, 4.6 × 250 mm); mobile phase: 10-70%
of acetonitrile in phosphate buffer (pH = 6.8) in 15 min, 70% acetonitrile to 25 min; flow rate 1.0
mL/min; injection volume: 10 μL; tR: 11.270 min (97.9% at 254 nm).
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(R)-Methyl 2-(4-(3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamido)-3-
isopropoxybenzamido)propanoate (23). Synthesized according to General procedure E from 22
(611 mg, 2.18 mmol), with 3,4-dichloro-5-methyl-1H-pyrrole-2-carboxylic acid (0.508 g, 2.62
mmol) instead of 4,5-dibromo-1H-pyrrole-2-carboxylic acid as a reagent. Instead of 2M solution
of oxalyl chloride in dichloromethane, 98% oxalyl chloride (0.905 mL, 10.48 mmol) was used.
During extraction a precipitate formed which was filtered off. The mother liquor was extracted and
the filtered part of the compound was combined with the part after extraction. To the crude product
diethyl ether (10 mL) and a few drops of methanol were added, the obtained suspension was
sonicated, filtered, washed with diethyl ether (2 × 5 mL) and dried to afford 23 as off-white solid
(762 mg). Yield 73% (0.762 g); mp 220-222 °C; [α]D25 -95.9 (c 0.231, DMF). IR (ATR) ν = 3361,
3258, 2992, 1739, 1632, 1522, 1495, 1415, 1309, 1215, 1106, 1053, 976, 830, 749 cm-1. 1H NMR
(400 MHz, DMSO-d6) δ = 1.36-1.38 (m, 6H, CH(CH3)2), 1.43 (d, 3H, 3J = 7.2 Hz, NHCHCH3),
2.52 (s, 3H, Pyrrole-CH3), 3.66 (s, 3H, COOCH3), 4.49 (quint, 1H, 3J = 7.2 Hz, NHCHCH3), 4.87
(spt, 1H, 3J = 6.0 Hz, CH(CH3)2), 7.57 (dd, 1H, 3J = 8.4 Hz, 4J = 1.6 Hz, Ar-H-6), 7.62 (d, 1H, 4J
= 1.6 Hz, Ar-H-2), 8.47 (d, 1H, 3J = 8.4 Hz, Ar-H-5), 8.74 (d, 1H, 3J = 6.8 Hz, NHCHCH3), 9.26
(s, 1H, CONHAr), 12.46 (s, 1H, Pyrrole-NH).13C NMR (100 MHz, DMSO-d6) δ = 10.75 (Pyrrole-
CH3), 16.78 (CH3), 21.77 (CH(CH3)2), 21.81 (CH(CH3)2), 48.31 (CH3), 51.87 (CH), 71.31
(CH(CH3)2), 108.60, 109.72, 111.68, 117.96, 118.64, 120.54, 128.40, 129.78, 131.23, 145.16,
156.21, 165.45 (Ar-CONH), 173.26 (COOCH3). MS (ESI) m/z = 454.1 ([M-H]-).  HRMS  for
C20H22Cl2N3O5: calculated 454.0937, found 454.0939. HPLC: Phenomenex Luna C18 column (5
µm, 4.6 × 250 mm); mobile phase: 10-70% of acetonitrile in phosphate buffer (pH = 6.8) in 15
min, 70% acetonitrile to 25 min; flow rate 1.0 mL/min; injection volume: 10 μL; tR: 11.270 min
(97.7% at 280 nm).
4,5-Dibromo-N-(4-((cyanomethyl)carbamoyl)phenyl)-1H-pyrrole-2-carboxamide (43a).
Synthesized according to General procedure E from 42 (210 mg, 1.2 mmol). Brown solid. Yield
50% (0.312 g); mp >300 °C; IR (ATR) ν = 3252, 1637, 1594, 1520, 1409, 1300, 1248, 1188, 987,
849, 752, 630 cm-1. 1H NMR (400 MHz, DMSO-d6) δ = 4.30 (d, 2H, 3J = 5.4 Hz, CH2),7.28 (d,
1H, 4J = 2.8 Hz,  Pyrrole-CH), 7.82-7.88 (m, 4H, 4×Ar-H), 9.11 (t, 1H, 3J = 5.4 Hz, NH), 10.09 (s,
1H, NHAr), 12.99 (d, 1H, 4J = 2.8 Hz,  Pyrrole-NH). 13C NMR (100 MHz, DMSO-d6) δ = 27.68,
98.28, 106.51, 114.29, 117.76, 119.06, 127.35, 127.58, 128.27, 142.17, 157.44, 166.09. MS (ESI)
m/z = 422.9 ([M-H]-),  HRMS for  C14H9Br2N4O2: calculated 422.9084, found 422.9092. HPLC:
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Phenomenex Luna C18 column (5 µm, 4.6 × 250 mm); mobile phase: 10-70% of acetonitrile in
phosphate buffer (pH = 6.8) in 15 min, 70% acetonitrile to 25 min; flow rate 1.0 mL/min; injection
volume: 10 μL; tR: 13.940 min (95.4% at 220 nm).
3,4-Dichloro-N-(4-((cyanomethyl)carbamoyl)phenyl)-5-methyl-1H-pyrrole-2-
carboxamide (43b). Synthesized according to General procedure E from 42 (250.5 mg, 1.43
mmol), with 3,4-dichloro-5-methyl-1H-pyrrole-2-carboxylic acid (0.333 g, 1.72 mmol) instead of
4,5-dibromo-1H-pyrrole-2-carboxylic  acid  as  a  reagent.  During  extraction  a  precipitate  formed
which was filtered off. The mother liquor was extracted and the filtered part of the compound was
combined with the part after extraction. The crude product was triturated with methanol and diethyl
ether (2:1, 8 mL) and filtered off to afford 43b (0.380 g) as light brown solid. Yield 79% (0.380
g); mp 277-278 °C. IR (ATR) ν = 3385, 3243, 1641, 1594, 1527, 1470, 1311, 1254, 1186, 846, 588
cm-1. 1H NMR (400 MHz, DMSO-d6) δ = 2.24 (s, 3H, Pyrrole-CH3), 4.30 (d, 2H, 3J = 5.4 Hz, CH2),
7.77 (d, 2H, 3J = 8.7 Hz, 2×Ar-H), 7.87 (d, 2H, 3J = 8.7 Hz, 2×Ar-H), 9.11 (t, 1H, 3J = 5.4 Hz,
NH), 9.73 (s, 1H, NHAr), 12.25 (s, 1H, Pyrrole-NH). 13C NMR (100 MHz, DMSO-d6) δ 10.80
(Pyrrole-CH3), 27.67 (CH2), 108.62, 111.82, 117.76, 119.07, 119.36, 127.49, 128.31, 128.39,
141.88, 157.35, 166.04. MS (ESI) m/z =  349.0  ([M-H]-),  HRMS for  C15H11Cl2N4O2: calculated
349.0251, found 349.0259. HPLC: Phenomenex Luna C18 column (5 µm, 4.6 × 250 mm); mobile
phase: 10-70% of acetonitrile in phosphate buffer (pH = 6.8) in 15 min, 70% acetonitrile to 25 min;
flow rate 1.0 mL/min; injection volume: 10 μL; tR: 15.053 min (97.7% at 280 nm).
Diethyl 2-(4-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzamido)malonate (46a).
Synthesized according to General procedure E from 45 (144 mg, 0.488 mmol). The crude product
was triturated with diethyl ether (5 mL), filtered off and dried to afford 46 (0.160 g) as light brown
solid. Yield 50% (0.160 g); mp 191-193 °C; IR (ATR) ν = 3398, 3303, 3229, 2987, 1730, 1643,
1514, 1412, 1328, 1216, 1170, 1027, 849, 627 cm-1. 1H NMR (400 MHz, DMSO-d6) δ = 1.23 (t,
6H, 3J = 7.1 Hz, 2×COOCH2CH3), 4.15-4.27 (m, 4H, 2×COOCH2CH3), 5.30 (d, 2H, 3J = 7.6 Hz,
NHCH), 7.29 (d, 1H, 4J = 2.8 Hz,  Pyrrole-CH), 7.83 (d, 2H, 3J = 8.9 Hz, 2×Ar-H), 7.92 (d, 2H, 3J
= 8.9 Hz, 2×Ar-H), 9.21(d, 1H, 3J = 7.6 Hz, NHCH), 10.09 (s, 1H, NHAr), 12.99 (d, 1H, 4J = 2.8
Hz,  Pyrrole-NH). 13C NMR (100 MHz, DMSO-d6) δ = 13.87, 56.47, 61.64, 98.28, 106.49, 114.27,
118.97, 127.39, 127.61, 128.57, 142.12, 157.45, 165.83, 166.64. MS (ESI) m/z = 542.0 ([M-H]-),
HRMS for C19H18Br2N3O6: calculated 541.9557, found 541.9562. HPLC: Phenomenex Luna C18
column (5 µm, 4.6 × 250 mm); mobile phase: 10-70% of acetonitrile in phosphate buffer (pH =
40
6.8) in 15 min, 70% acetonitrile to 25 min; flow rate 1.0 mL/min; injection volume: 10 μL; tR:
16.583 min (98.2% at 220 nm).
Diethyl 2-(4-(3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamido)benzamido)malonate
(46b). Synthesized according to General procedure E from 45 (591 mg, 2.01 mmol), with 3,4-
dichloro-5-methyl-1H-pyrrole-2-carboxylic acid (0.468 g, 2.41 mmol) instead of 4,5-dibromo-1H-
pyrrole-2-carboxylic acid as a reagent. During extraction a precipitate formed which was filtered
off. The mother liquor was extracted and the filtered part of the compound was combined with the
part after extraction. The crude product was triturated with methanol and diethyl ether (2:1, 8 mL)
and filtered off to afford 46b (0.265 g) as light brown solid. Yield 27% (0.265 g); mp 173-175 °C;
IR (ATR) ν = 3391, 3252, 2986, 1754, 1643, 1594, 1520, 1475, 1344, 1233, 1177, 1024, 849, 736,
564 cm-1. 1H NMR (400 MHz, DMSO-d6) δ = 1.24 (t, 6H, 3J = 7.1 Hz, 2×COOCH2CH3), 2.25 (s,
3H, Pyrrole-CH3), 4.15-4.27 (m, 4H, 2×COOCH2CH3), 5.30 (d, 2H, 3J = 7.5 Hz, NHCH), 7.77 (d,
2H, 3J = 8.6 Hz, 2×Ar-H), 7.92 (d, 2H, 3J = 8.6 Hz, 2×Ar-H), 9.22 (d, 1H, 3J = 7.5 Hz, NHCH),
9.71 (s, 1H, NHAr), 12.24 (s, 1H, Pyrrole-NH). 13C NMR (100 MHz, DMSO-d6) δ  10.81, 13.87,
56.47, 61.65, 108.61, 111.78, 118.99, 119.39, 127.54, 128.39, 128.62, 141.83, 157.36, 165.80,
166.64. MS (ESI) m/z = 468.1 ([M-H]-),  HRMS for C20H20Cl2N3O6: calculated 468.0725, found
468.0725. HPLC: Phenomenex Luna C18 column (5 µm, 4.6 × 250 mm); mobile phase: 10-70%
of acetonitrile in phosphate buffer (pH = 6.8) in 15 min, 70% acetonitrile to 25 min; flow rate 1.0
mL/min; injection volume: 10 μL; tR: 17.710 min (96.2% at 280 nm).
3,4-Dichloro-5-methyl-N-(4-(5-oxo-4,5-dihydro-1H-tetrazol-1-yl)phenyl)-1H-pyrrole-2-
carboxamide (50). Synthesized according to General procedure E from 49 (356 mg, 2.01 mmol),
with 3,4-dichloro-5-methyl-1H-pyrrole-2-carboxylic acid (0.468 g, 2.41 mmol) instead of 4,5-
dibromo-1H-pyrrole-2-carboxylic acid as a reagent. The mixture was cooled on ice bath and the
precipitate filtered off. The crude product was purified with flash column chromatography using
dichloromethane/methanol  (10/1)  as  an  eluent  to  afford 50 (0.040 g) as pink solid. Yield 10%
(0.040 g); mp >300 °C; IR (ATR) ν = 3387, 3233, 1743, 1641, 1542, 1514, 1425, 1249, 1097,
1042, 832, 740 cm-1. 1H NMR (400 MHz, DMSO-d6) δ = 2.25 (s, 3H, Pyrrole-CH3), 7.78 (d, 2H,
3J =  8.7  Hz,  2×Ar-H),  8.36  (d,  2H, 3J = 8.7 Hz, 2×Ar-H), 9.79 (s, 1H, NHAr),12.56 (br s, 1H,
Pyrrole-CH3), signal for 5-oxotetrazole NH is not seen. 13C NMR (100 MHz, DMSO-d6) δ = 10.75
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(Pyrrole-CH3), 108.63, 112.51, 118.90, 119.02, 120.16, 127.62, 131.98, 136.23, 156.95, 159.33.
MS (ESI) m/z = 351.0 ([M-H]-), HRMS for C13H9Cl2N6O2: calculated 351.0172, found 351.0158.
HPLC: Phenomenex Luna C18 column (5 µm, 4.6 × 250 mm); mobile phase: 10-70% of
acetonitrile in phosphate buffer (pH = 6.8) in 15 min, 70% acetonitrile to 25 min; flow rate 1.0
mL/min; injection volume: 10 μL; tR: 10.710 min (97.2% at 280 nm).
Ethyl 7-(3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamido)-1-ethyl-4-oxo-1,4-
dihydroquinoline-3-carboxylate (56). Synthesized according to General procedure E from 55
(349 mg, 1.34 mmol), with 3,4-dichloro-5-methyl-1H-pyrrole-2-carboxylic acid (0.312 g, 1.61
mmol) instead of 4,5-dibromo-1H-pyrrole-2-carboxylic acid as a reagent. During extraction a
precipitate formed which was filtered off. The solid was recrystallized twice from THF to afford
56 (0.280 g) as yellow solid. Yield 42% (0.280 g); mp 277-280 °C. IR (ATR) ν = 3320, 3110, 2983,
2886, 1697, 1671, 1618, 1565, 1458, 1301, 1260, 1096, 1033, 1016, 800, 730, 595 cm-1. 1H NMR
(400 MHz, DMSO-d6) δ = 1.29 (t, 3H, 3J =  7.1  Hz,COOCH2CH3), 1.44 (t, 3H, 3J =  7.1  Hz,
NCH2CH3), 2.25 (s, 3H, Pyrrole-CH3), 4.23 (q, 2H, 3J = 7.1 Hz, COOCH2CH3), 4.34 (q, 2H, 3J =
7.1 Hz, NCH2CH3), 7.65 (dd, 1H, 3J = 8.8 Hz, 4J = 1.7 Hz, quinoline-H-6), 8.21 (d, 1H, 3J = 8.8
Hz, quinoline-H-5), 8.26 (d, 1H, 4J = 1.7 Hz, quinoline-H-8), 8.69 (s, 1H, CHNCH2CH3), 9.94 (s,
1H, NHAr), 12.32 (br s, 1H, Pyrrole-NH). 13C NMR (100 MHz, DMSO-d6) δ 10.82 (Pyrrole-CH3),
14.03, 14.31, 48.13, 59.64, 105.97, 108.78, 110.04, 112.09, 117.11, 119.17, 124.02, 127.37,
128.71, 139.24, 142.48, 149.15, 157.66, 164.65, 172.27. MS (ESI) m/z = 434.1 ([M-H]-), HRMS
for C20H18Cl2N3O4: calculated 434.0670, found 434.0674. HPLC: Phenomenex Luna C18 column
(5 µm, 4.6 × 250 mm); mobile phase: 10-70% of acetonitrile in phosphate buffer (pH = 6.8) in 15
min, 70% acetonitrile to 25 min; flow rate 1.0 mL/min; injection volume: 10 μL; tR: 15.677 min
(98.7% at 220 nm).
Ethyl 5-(3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamido)-1H-indole-2-carboxylate (60).
Synthesized according to General procedure E from 59 (472 mg, 1.97 mmol), with 3,4-dichloro-5-
methyl-1H-pyrrole-2-carboxylic acid (0.458 g, 2.36 mmol) instead of 4,5-dibromo-1H-pyrrole-2-
carboxylic acid as a reagent. After the addition of pyridine the reaction mixture was stirred for 12
h. A green-brown precipitate formed which was filtered off. the crude product was triturated with
ethanol and diethyl ether (2:1, 8 mL) to afford 60 (0.675 g) as brown solid. Yield 79% (0.675 g);
mp 264-267 °C; IR (ATR) ν = 3404, 3288, 3239, 1686, 1642, 1530, 1488, 1418, 1255, 1202, 1155,
1090, 1023, 806, 767 cm-1. 1H  NMR  (400  MHz,  DMSO-d6): δ = 1.35 (t, 3H, 3J =  7.1  Hz,
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COOCH2CH3), 2.24 (s, 3H, Pyrrole-CH3), 4.35 (q, 2H, 3J = 7.1 Hz, COOCH2CH3), 7.14-7.15 (m,
1H, Ar-H), 7.41-7.48 (m, 2H, 2×Ar-H), 8.03-8.06 (m, 1H, Ar-H), 9.34 (s, 1H, NHAr), 11.88 (s,
1H, Pyrrole-NH/indole-NH), 12.15 (s, 1H, Pyrrole-NH/indole-NH). 13C NMR (100 MHz, DMSO-
d6) δ 10.75 (Pyrrole-CH3), 14.29 (COOCH2CH3), 60.41 (COOCH2CH3), 107.65, 108.24, 110.71,
112.59, 112.67, 119.67, 119.80, 126.57, 127.60, 127.95, 131.42, 134.46, 157.09, 161.21. MS (ESI)
m/z = 378.0 ([M-H]-),  HRMS for  C17H14Cl2N3O3: calculated 378.0422, found 378.0429 HPLC:
Phenomenex Luna C18 column (5 µm, 4.6 × 250 mm); mobile phase: 10-70% of acetonitrile in
phosphate buffer (pH = 6.8) in 15 min, 70% acetonitrile to 25 min; flow rate 1.0 mL/min; injection
volume: 10 μL; tR: 18.893 min (98.7% at 280 nm).
General procedure F. Synthesis of Compounds 8a-d, 16 and 34 (with 8b as an Example). To
a solution of compound 8b (0.050 g, 0.086 mmol) in a mixture of methanol (3 mL) and THF (3
mL) 1 M NaOH (0.344 mL, 0.344 mmol) was added. The mixture was stirred at rt for 15 h. The
solvent was removed under reduced pressure, EtOAc (10 mL) and 1M HCl (10 mL) were added to
the residue. The organic phase was washed with brine (2 × 10 mL), dried over Na2SO4, filtered and
the solvent removed under reduced pressure to afford 8b (0.038 g) as white solid.
tert-Butyl 4-(2-(3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamido)-5-((2-methoxy-2-
oxoethyl)carbamoyl)phenoxy)piperidine-1-carboxylate (8b). White solid; yield 77 % (0.038 g);
mp 223-225 °C; IR (ATR) ν = 3355, 3260, 2966, 2910, 1733, 1667, 1634, 1522, 1427, 1326, 1256,
1134, 1047, 838, 815, 765 cm-1. 1H NMR (400 MHz, DMSO-d6): δ = 1.42 (s, 9H, 3 × CH3), 1.51-
1.62 (m, 2H, 2×(CH)CH-O-Ar), 2.00-2.09 (m, 2H, 2×(CH)CH-O-Ar), 2.24 (s, 3H, Pyrrole-CH3),
3.03-3.16 (m, 2H, 2×CHNBoc), 3.79-3.87 (m, 2H, 2×CHNBoc), 3.93 (d, 2H, 3J =  5.6  Hz,
NHCH2COOH), 4.74-4.82 (m, 1H, CH-O-Ar), 7.56 (dd, 1H, 3J = 8.6 Hz, 4J = 1.7 Hz, Ar-H-6),
7.65 (d, 1H, 4J = 1.7 Hz, Ar-H-2), 8.46 (d, 1H, 3J = 8.6 Hz, Ar-H-5), 8.82 (t, 1H, 3J = 5.6 Hz,
NHCH2COOCH3), 9.16 (s, 1H, NHAr), 12.46 (s, 1H, Pyrrole-NH), 12.53 (br s, 1H, COOH). 13C
NMR (100 MHz, DMSO-d6) δ 10.74 (Pyrrole-CH3), 28.01 (3 × CH3), 30.63, 41.23, 74.11, 78.89,
108.59, 109.74, 111.83, 118.49, 118.69, 120.59, 128.79, 129.80, 131.11, 144.90, 153.96, 156.33,
165.74, 171.42, two aliphatic signal are not seen. MS (ESI) m/z = 567.1 ([M-H]-), HRMS for
C25H29Cl2N4O7: calculated 567.1421, found 567.1413; HPLC: Phenomenex Luna C18 column (5
µm, 4.6 × 250 mm); mobile phase: 10-70% of acetonitrile in phosphate buffer (pH = 6.8) in 20
min, 70% acetonitrile to 25 min; flow rate 1.0 mL/min; injection volume: 10 μL; tR: 16.333 min
(99.2% at 254 nm).
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General procedure G. Synthesis of Compounds 9a-b and 17 (with 9a as an Example). Compound
8a (0.020 g, 0.031 mmol) was dissolved in HCl 1M solution in acetic acid (4 mL) and in 1 mL of
DMF. The mixture was stirred for 8 h. After the completion of the reaction the solvent was removed
under reduced pressure and the solid was washed with diethyl ether (2 × 5 mL) to obtain 9a (0.014
g) as brown solid.
4-(5-((Carboxymethyl)carbamoyl)-2-(4,5-dibromo-1H-pyrrole-2-
carboxamido)phenoxy)piperidin-1-ium chloride (9a). Brown solid; yield 78 % (0.014 g); mp
>300 °C; IR (ATR) ν = 3427, 3128, 2962, 1731, 1667, 1637, 1519, 1391, 1277, 1199, 1181, 1023,
752, 615 cm-1. 1H NMR (400 MHz, DMSO-d6): δ = 1.91-2.01 (m, 2H, 2×(CH)CH-O-Ar), 2.05-
2.15 (m, 2H, 2×(CH)CH-O-Ar), 3.06-3.15(m, 2H, 2×CHNH2+), 3.23-3.31 (m, 2H, 2×CHNH2+,
overlapped with the signal for water), 3.93 (d, 2H, 3J = 5.4 Hz, NHCH2COOCH3), 4.75-4.82 (m,
1H, CH-O-Ar), 7.18 (d, 1H, 4J = 2.5 Hz,  Pyrrole-CH), 7.54 (d, 1H, 3J = 8.3 Hz, Ar-H-4), 7.61 (s,
1H, Ar-H-6), 7.85 (d, 1H, 3J = 8.3 Hz, Ar-H-3), 8.65 (br s, 1H, Ha from NH2+), 8.81 (br s, 1H, Hb
from NH2+), 8.89 (t, 1H, 3J =  5.4  Hz,  NHCH2COOCH3),9.38 (s, 1H, NHAr), 12.61 (br s, 1H,
COOH), 13.07 (s, 1H, Pyrrole-NH). 13C NMR (100 MHz,  DMSO-d6): δ = 26.85, 41.22, 69.92,
98.39, 112.65, 112.68, 114.17, 120.16, 124.10, 127.63, 130.22, 130.76, 148.31, 157.17, 165.70,
171.33, one aliphatic signal is not seen. MS (ESI) m/z = 541.0 ([M-H]-), HRMS for C19H19Br2N4O5:
calculated 540.9717, found 540.9722. HPLC: Phenomenex Luna C18 column (5 µm, 4.6 × 250
mm); mobile phase: 10-70% of acetonitrile in phosphate buffer (pH = 6.8) in 20 min, 70%
acetonitrile to 25 min; flow rate 1.0 mL/min; injection volume: 10 μL; tR: 10.250 min (95.3% at
220 nm).
General procedure H. Synthesis of Compounds 9c-d, 10a-b and 18 (with 9c as an Example).
Compound 8c (0.050 g, 0.086 mmol) was dissolved in HCl 4M solution in dioxane (4 mL). The
mixture was stirred for 4 h. After the completion of the reaction the solvent removed under reduced
pressure and the solid was washed with diethyl ether (2 × 5 mL)  to obtain 9c (0.018 g) as brown
solid.
(S)-4-(5-((1-Carboxyethyl)carbamoyl)-2-(3,4-dichloro-5-methyl-1H-pyrrole-2-
carboxamido)phenoxy)piperidin-1-ium chloride (9c). Brown solid; yield 40% (0.018 g); mp
>300 °C. [α]D25 +7.5 (c 0.200, MeOH). IR (ATR) ν = 3363, 3252, 2945, 2808, 2723, 1721, 1647,
1593, 1514, 1260, 1207, 1031, 991, 863, 759, 609 cm-1. 1H NMR (400 MHz, DMSO-d6) δ = 1.41
(d, 3H, 3J = 7.2 Hz, CH3), 1.85-1.96 (m, 2H, 2×(CH)CH-O-Ar), 2.16-2.24 (m, 5H, 2×(CH)CH-O-
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Ar, Pyrrole-CH3), 3.04-3.16 (m, 2H, 2×CHNH2+), 3.76-3.85 (m, 2H, 2×CHNH2+), 4.38-4.46 (m,
1H, CH-O-Ar), 4.86-4.93 (m, 1H, NHCHCOOH), 7.61 (m, 1H, Ar-H-4), 7.65 (s, 1H, Ar-H-6), 8.44
(d, 1H, 3J =  8.4  Hz,  Ar-H-3),  8.57  (br  s,  1H,  Ha  from  NH2+), 8.64 (d, 1H, 3J =  7.2  Hz,
NHCHCOOH), 8.72 (br s, 1H, Hb from NH2+), 9.16 (s, 1H, NHAr), 12.48 (s, 1H, Pyrrole-NH),
12.57 (br s, 1H, COOH). 13C NMR (100 MHz, DMSO-d6) δ = 10.76 (Pyrrole-CH3), 16.93 (CH3),
27.52, 40.99, 48.22, 70.95, 108.61, 110.03, 111.86, 118.58, 118.71, 120.86, 128.99, 129.75,
130.89, 144.71, 156.37, 165.29, 174.25. MS (ESI) m/z = 481.1 ([M-H]-), HRMS for
C21H23Cl2N4O5: calculated 481.1041, found 481.1046. HPLC: Phenomenex Luna C18 column (5
µm, 4.6 × 250 mm); mobile phase: 10-70% of acetonitrile in phosphate buffer (pH = 6.8) in 15
min, 70% acetonitrile to 25 min; flow rate 1.0 mL/min; injection volume: 10 μL; tR: 11.827 min
(95.6% at 280 nm).
(R)-3,4-Dichloro-N-(4-((1-hydrazinyl-1-oxopropan-2-yl)carbamoyl)-2-isopropoxyphenyl)-5-
methyl-1H-pyrrole-2-carboxamide (24).
To  the  solution  of 23 (0.400 g, 0.876 mmol) in anhydrous methanol and anhydrous
tetrahydrofurane (1:1, 32 mL) hydrazine monohydrate (0.42 mL, 8.76 mmol) was added and the
reaction mixture stirred at 68 °C for 15 h. The obtained suspension was cooled on ice bath, the
precipitate filtered off and dried to give 24 (0.305 mg) as white solid. Yield 77% (0.305 g); mp
241-243 °C; [α]D25 -33.7 (c 0.139, THF). IR (ATR) ν = 3363, 3246, 2975, 1648, 1599, 1522, 1416,
1255, 1213, 1115, 976, 749, 646 cm-1. 1H NMR (400 MHz, DMSO-d6) δ = 1.32-1.38 (m, 9H,
CH(CH3)2, CH3), 2.24 (s, 3H, Pyrrole-CH3),  4.22 (br s,  2H, NH2), 4.47 (quint, 1H, 3J = 7.2 Hz,
CONHCH), 4.88 (spt, 1H, 3J = 5.8 Hz, CH(CH3)2), 7.56 (dd, 1H, 3J = 8.4 Hz, 4J = 1.7 Hz, Ar-H-
5), 7.64 (d, 1H, 4J = 1.7 Hz, Ar-H-3), 8.44-8.46 (m, 2H, Ar-H-6,CONHCH), 9.18 (s, 1H, NHNH2),
9.26 (s, 1H, CONHAr), 11.76 (s, 1H, Pyrrole-NH). 13C NMR (100 MHz, DMSO-d6) δ = 10.73
(Pyrrole-CH3), 18.12, 21.77 (CH(CH3)2), 21.82 (CH(CH3)2), 47.14, 71.32 (CH(CH3)2), 108.62,
109.71, 111.89, 117.89, 118.65, 120.63, 128.89, 129.80, 131.03, 145.08, 156.21, 165.31 (Ar-
CONH), 171.81. MS (ESI) m/z = 454.1 ([M-H]-), HRMS for C19H22Cl2N5O4: calculated 454.1041,
found 454.1049. HPLC: Phenomenex Luna C18 column (5 µm, 4.6 × 250 mm); mobile phase: 10-
70% of acetonitrile in phosphate buffer (pH = 6.8) in 15 min, 70% acetonitrile to 25 min; flow rate
1.0 mL/min; injection volume: 10 μL; tR: 16.900 min (99.0% at 254 nm).
(R)-3,4-Dichloro-N-(2-isopropoxy-4-((1-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-
yl)ethyl)carbamoyl)phenyl)-5-methyl-1H-pyrrole-2-carboxamide (25).
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To the solution of 24 (0.260 g, 0.569 mmol) in a mixture of 1,4-dioxane and anhydrous
dimethylformamide (1:2, 30 mL) 1,1′-thiocarbonyldiimidazole (0.254 mg, 1.43 mmol) was added
and the reaction mixture was stirred at 100 °C for 15 h. The solvent was removed under reduced
pressure and the crude product was triturated with water and ethanol (1:1, 8 mL) to afford 25 (0.058
g) as pale yellow solid. Yield 20% (0.058 g); mp 246-247 °C; [α]D25 -15.1 (c 0.200, THF). IR
(ATR) ν = 3356, 3255, 2978, 1646, 1597, 1512, 1492, 1415, 1264, 1213, 1108, 985, 605 cm-1. 1H
NMR (400 MHz, DMSO-d6) δ = 1.35-1.38 (m, 6H, CH(CH3)2), 1.55 (d, 3J = 7.0 Hz, CH3)     2.25
(s, 3H, Pyrrole-CH3), 4.86 (spt, 1H, 3J =  6.0  Hz,  CH(CH3)2),5.25 (quint, 1H, 3J =  7.2  Hz,
CONHCH),7.56 (dd, 1H, 3J = 8.4 Hz, 4J = 1.7 Hz, Ar-H-5), 7.61 (d, 1H, 4J = 1.7 Hz, Ar-H-3),
8.48 (d, 1H, 3J = 8.4 Hz, Ar-H-6), 8.99 (d, 3J = 7.2 Hz, CONHCH), 9.27 (s, 1H, CONHAr), 12.46
(s, 1H, Pyrrole-NH), 14.48 (br s, 1H, oxadiazolone-NH). 13C  NMR  (100  MHz,  DMSO-d6) δ =
10.76 (Pyrrole-CH3), 17.16, 21.77 (CH(CH3)2), 21.80 (CH(CH3)2), 41.48, 71.39 (CH(CH3)2),
108.63, 109.77, 111.67, 118.02, 118.63, 120.56, 128.07, 129.85, 131.47, 145.25, 156.24, 164.33,
165.20, 177.84. MS (ESI) m/z = 496.1 ([M-H]-), HRMS for C20H20Cl2SN5O4: calculated 496.0615,
found 496.0613.
General procedure I. Synthesis of Compounds 27, 29, 33 and 39 (with 27 as an Example). To a
solution of 3,4-dichloro-5-methylpyrrole-2-carboxylic acid (0.258 g, 1.33 mmol) in anhydrous
dichloromethane (20 mL), oxalyl chloride (0.46 mL, 5.32 mmol) was added dropwise and the
solution stirred at rt for 15 h under argon atmosphere. The solvent was evaporated under reduced
pressure, fresh anhydrous THF (10 mL), 26 (0.200 g, 1. 16 mmol) and pyridine (5 mL) were added
and the reaction mixture stirred under argon atmosphere at rt for 15 h. Solvent was removed under
reduced pressure, the residue dissolved in ethyl acetate (15 mL) and washed with HCl 1M solution
(15 mL) and brine (2 × 15 mL). The organic phase was dried over Na2SO4, filtered and the solvent
removed under reduced pressure. The solid was recrystallized from MeOH (8 mL) and acetonitrile
(8 mL) to afford 27 (0.150 g) as light brown solid.
3,4-Dichloro-5-methyl-N-(4-sulfamoylphenyl)-1H-pyrrole-2-carboxamide (27). Light
brown solid; yield 37% (0.150 g); mp 290-292 °C. IR (ATR) ν = 3388, 3259, 1755, 1646, 1592,
1524, 1474, 1315, 1264, 1159, 886, 690, 566, 536 cm-1. 1H NMR (400 MHz, DMSO-d6): δ = 2.24
(s, 3H, Pyrrole-CH3), 7.30 (s, 2H, NH2), 7.78-7.85 (m, 4H, 4×Ar-H), 9.82 (s, 1H, NHAr). 13C NMR
(100 MHz, DMSO-d6) δ = 10.79 (Pyrrole-CH3), 108.71, 112.08, 119.19, 119.39, 126.64, 128.51,
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138.55, 141.56, 157.41. MS (ESI) m/z = 346.0 ([M-H]-), HRMS for C12H10Cl2SN3O3: calculated
345.9827, found 345.9820. HPLC: Phenomenex Luna C18 column (5 µm, 4.6 × 250 mm); mobile
phase: 10-70% of acetonitrile in phosphate buffer (pH = 6.8) in 15 min, 70% acetonitrile to 25 min;
flow rate 1.0 mL/min; injection volume: 10 μL; tR: 16.267 min (96.5% at 254 nm).
Methyl 2-(4-nitrophenylsulfonamido)acetate (31) [51]. To a solution of glycine methyl ester
hydrochloride (0.566 g, 4.51 mmol) and triethylamine (1.87 mL, 13.5 mmol) in DCM (20 mL) 4-
nitrobenzene-1-sulfonyl chloride (30) (1.00 g, 4.51 mmol), previously dissolved in DCM (10 mL),
was added dropwise at 0 °C. The mixture was allowed to stir at rt for 12 h. Solvent was removed
under reduced pressure, the residue dissolved in ethyl acetate (15 mL) and washed with HCl 1M
solution (15 mL) and brine (2 × 15 mL). The organic phase was dried over Na2SO4, filtered and
the solvent removed under reduced pressure. The obtained solid was recrystallized from MeOH (8
mL) to afford 31 (0.840 g) as white crystals. Yield 68% (0.840 g); mp 130-131 °C. IR (ATR) ν =
3251, 3108, 2959, 1602, 1726, 1525, 1346, 1333, 1157, 1090, 823, 734, 536 cm-1. 1H NMR (400
MHz, DMSO-d6): δ = 3.52 (s, 3H, OCH3), 3.83 (d, 2H, 3J = 6.2 Hz, CH2), 8.05 (d, 2H, 3J = 8.9 Hz,
Ar-H-2,6), 8.41 (d, 2H, 3J = 8.9 Hz, Ar-H-3,5), 8.66 (t, 1H, 3J = 6.2 Hz, NH). MS (ESI) m/z = 273.0
([M-H]-), HRMS for C9H9SN2O6: calculated 273.0187, found 273.0181.
Methanesulfonamide (36). A solution of methanesulfonyl chloride (35) (7.97 mL, 103 mmol)
in anhydrous THF (50 mL) was saturated with gaseous ammonia at 0 °C for 0.5 h. The resulting
white suspension was washed thoroughly with EtOAc, filtered through Celite® and the mother
liquor evaporated to give 36 (8.40 g) as white crystals. Yield 85% (8.40 g); mp 91-92 °C. 1H NMR
(400 MHz, DMSO-d6): δ = 2.91 (s, 3H, CH3), 6.80 (br s, 2H, NH2). MS (ESI) m/z = 94.0 ([M-H]-
).
N-(Methylsulfonyl)-4-nitrobenzamide (37) [52]. A mixture of 36 (0.769 g, 8.08 mmol) and 4-
nitrobenzoyl chloride (1.50 g, 8.08 mmol) in anhydrous DCM was cooled to 0 °C. To this
suspension triethylamine (3.41 mL, 24.2 mmol) was added and the mixture was allowed to stir at
rt for 12 h. The solvent was removed under reduced pressure, EtOAc (10 mL) and 1M HCl (10
mL) were added to the residue and the phases were separated. The organic phase was washed with
brine (2 × 10 mL), dried over Na2SO4, filtered and the solvent removed under reduced pressure.
The solid wass triturated with methanol and diethyl ether (2:1, 8 mL) and filtered off to give 37
(0.950 g) as white crystals. Yield 48% (8.40 g); mp 115-118 °C (116 °C, [52]). IR (ATR) ν = 3251,
3108, 2959, 1602, 1726, 1525, 1346, 1333, 1157, 1090, 823, 734, 536 cm-1. 1H NMR (400 MHz,
47
DMSO-d6) δ = 3.41 (s, 3H, CH3), 8.16 (d, 2H, 3J = 8.5 Hz, Ar-H-2,6), 8.36 (d, 2H, 3J = 8.5 Hz, Ar-
H-3,5), 12.54 (br s, 1H, NH). MS (ESI) m/z = 243.0 ([M-H]-), HRMS for C8H7SN2O5: calculated
243.0080, found 243.0076.
1-(4-Nitrophenyl)-1H-tetrazol-5(4H)-one (48) [53]. A mixture of 4-nitrobenzoyl chloride (47)
(2.00 g, 10.78 mmol) and azidotrimethylsilane (7.85 mL, 59.29 mmol) was heated at 90 °C for 12
h. The mixture was cooled on an ice bath for 0.5 h and the precipitate was filtered off. The obtained
solid was triturated with methanol and diethyl ether (2:1, 8 mL) and filtered off to give 37 (0.870
g) as light brown solid. Yield 39% (0.870 g); mp 214-217 °C (216-217 °C, [53]). IR (ATR) ν =
3119, 3028, 1716, 1595, 1519, 1332, 1139, 1036, 964, 856, 731, 654 cm-1. 1H NMR (400 MHz,
DMSO-d6): δ = 8.21 (d, 2H, 3J = 9.2 Hz, Ar-H-2,6), 8.36 (d, 2H, 3J = 9.2 Hz, Ar-H-3,5), 15.00 (br
s, 1H, NH). MS (ESI) m/z = 208.1 ([M+H]+).
Diethyl 2-(((3-nitrophenyl)amino)methylene)malonate (52) [54]. 3-Nitroaniline (51) (5.00 g,
36.19 mmol) and diethyl ethoxymethylenemalonate (7.31 mL, 36.19 mmol) were heated at 90 °C
for 3 h. The reaction mixture was cooled in an ice bath for 1 h and the precipitate was filtered off.
The obtained solid was recrystallized from ethanol (12 mL) and dried to give 52 (7.00 g) as yellow
solid. Yield 63% (7.00 g); mp 80-82 °C (80 °C, [54]). IR (ATR) ν = 2982, 1689, 1642, 1603, 1529,
1346, 1241, 1091, 1020, 729, 733, 665, 570 cm-1. 1H NMR (400 MHz, CDCl3): δ = 1.35-1.43 (m,
6H, 2×CH2CH3)), 4.27-4.38 (m, 4H, 2×CH2CH3), 7.44-7.47 (m, 1H, Ar-H), 7.56-7.60 (m, 1H, Ar-
H), 7.99-8.03 (m, 2H, Ar-H), 8.54 (d, 1H, 3J = 12.0 Hz, CH), 11.21 (d, 1H, 3J = 12.0 Hz, NH). MS
(ESI) m/z = 307.1 ([M-H]-), HRMS for C14H15N2O6: calculated 307.0935, found 307.0930.
Ethyl 7-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylate (53) [55]. Compound 52 (6.91 g,
22.41 mmol) dissolved in diphenyl ether (25 mL) was refluxed (260 °C) for 2.5 h with a heating
mantle, equipped with a thermometer and an a reflux condenser. The resulting sticky suspension
was diluted with acetone and filtered off. The solid was recrystallized from DMSO (15 mL) to
afford 53 (4.00 g) as pale yellow solid. Yield 68% (4.00 g); mp 269-272 °C. IR (ATR) ν = 3093,
2992, 1689, 1634, 1614, 1565, 1515, 1350, 1274, 1195, 1138, 912, 793, 626 cm-1. 1H NMR (400
MHz, DMSO-d6): δ = 1.30 (t, 3H, 3J = 7.1 Hz, CH3), 4.24 (q, 2H, 3J = 7.1 Hz, CH2), 8.15 (dd, 1H,
3J = 8.8 Hz, 4J = 2.0 Hz, Quinoline-H-6), 8.37 (d, 1H, 3J = 8.8 Hz, Quinoline-H-5), 8.51 (d, 1H, 4J
= 2.0 Hz, Quinoline-H-8), 8.77 (s, 1H, CHNH),12.66 (br s, 1H, NH). MS (ESI) m/z = 263.1
([M+H]+), HRMS for C12H11N2O5: calculated 263.0662, found 263.0668.
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Ethyl 1-ethyl-7-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylate (54) [56]. To a suspension
of 53 (2.92 g, 11.1 mmol) and potassium carbonate (1.69 g, 12.2 mmol) in DMF (75 mL) ethyl
bromide (0.91 mL, 12.2 mmol) was added. The mixture was stirred at 70 °C for 12 h. The solvent
was removed under reduced pressure, EtOAc (10 mL) and brine (10 mL) were added to the residue,
the phases were separated, and the organic phase was evaporated under reduced pressure. The solid
was triturated with methanol and diethyl ether (2:1, 10 mL) and filtered off to give 54 (1.90 g) as
yellow solid. Yield 59% (1.90 g); mp 220-222 °C (224-226 °C, [56]). IR (ATR) ν = 3115, 3054,
1674, 1642, 1600, 1564, 1523, 1453, 1347, 1316, 1209, 1134, 1095, 1011, 803, 783, 737 cm-1. 1H
NMR (400 MHz, DMSO-d6) δ = 1.30 (t, 3H, 3J = 7.0 Hz,COOCH2CH3), 1.41 (t, 3H, 3J = 7.1 Hz,
NCH2CH3), 4.26 (q, 2H, 3J = 7.0 Hz, COOCH2CH3), 4.54 (q, 2H, 3J = 7.1 Hz, NCH2CH3), 8.22
(dd, 1H, 3J = 8.8 Hz, 4J = 1.9 Hz, quinoline-H-6), 8.46 (d, 1H, 3J = 8.8 Hz, quinoline-H-5), 8.55
(d, 1H, 4J = 1.9 Hz, quinoline-H-8), 8.85 (s, 1H, CHNCH2CH3). MS (ESI) m/z = 291.1 ([M+H]+),
HRMS for C14H15N2O5: calculated 291.0976, found 291.0981.
General procedure J. Synthesis of Compounds 45, 55 and 59 (with 45 as an Example).
Compound 44 (1.40 g, 4.32 mmol) was dissolved in EtOH (80 mL) and the mixture was stirred for
30 min under argon atmosphere. Pd/C (0.140 g) was added and the reaction mixture was stirred
under hydrogen atmosphere for 3 h. The catalyst was filtered off and the solvent removed under
reduced pressure to obtain 45 (1.25 g) as white crystals.
Diethyl 2-(4-aminobenzamido)malonate (45). White crystals; yield 98% (1.25 g); mp 120-124
°C (122-123 °C, [57]). IR (ATR) ν = 3442, 3346, 3286, 2982, 1736, 1628, 1605, 1502, 1231, 1182,
1157, 1023, 771, 555 cm-1. 1H  NMR  (400  MHz,  DMSO-d6): δ = 1.22 (t, 6H, 3J =  7.1  Hz,
2×COOCH2CH3), 4.12-4.24 (m, 4H, 2×COOCH2CH3), 5.24 (d, 1H, 3J = 7.6 Hz, CH), 5.75 (s, 2H,
NH2), 6.55 (d, 2H, 3J = 8.7 Hz, Ar-H-3,5), 7.64 (d, 2H, 3J = 8.7 Hz, Ar-H-2,6), 8.74 (d, 1H, 3J =
7.6 Hz, NH). MS (ESI) m/z = 295.1 ([M+H]+), HRMS for C14H19N2O5: calculated 295.1298, found
295.1294.
General procedure K. Synthesis of Compounds 57 and 61 (with 57 as an Example). The starting
compound 56 (0.105 g, 0.24 mmol) was suspended in a mixture of EtOH and 1,4-dioxane (1:1, 20
mL). 1M NaOH (0.96 mL, 0.96 mmol) was added to the mixture which was allowed to stir at rt for
5 h. The solvent was removed under reduced pressure and 1M HCl (5 mL) was added dropwise to
the crude product. A pink colour developed while adding HCl and the solid was filtered off to give
57 (0.060 g) as pink solid.
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7-(3,4-Dichloro-5-methyl-1H-pyrrole-2-carboxamido)-1-ethyl-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (57). Pink solid; yield 61 % (0.060 g); mp 268-272 °C. IR
(ATR) ν = 3379, 3295, 3175, 1699, 1666, 1615, 1508, 1448, 1370, 1241, 1204, 1038, 801, 800,
574 cm-1. 1H NMR (400 MHz, DMSO-d6): δ = 1.49 (t, 3H, 3J = 7.0 Hz, NCH2CH3), 2.26 (s, 3H,
Pyrrole-CH3), 4.53 (q, 2H, 3J =  7.0  Hz,  NCH2CH3), 7.87 (dd, 1H, 3J =  8.8  Hz, 4J =  1.6  Hz,
quinoline-H-6), 8.35 (d, 1H, 3J = 8.8 Hz, quinoline-H-5), 8.50 (d, 1H, 4J = 1.6 Hz, quinoline-H-8),
9.06 (s, 1H, CHNCH2CH3), 10.28 (s, 1H, NHAr), 12.55 (br s, 1H, Pyrrole-NH), 15.41 (br s, 1H,
COOH). 13C NMR (100 MHz, DMSO-d6) δ = 10.81 (Pyrrole-CH3), 14.12, 49.17, 106.04, 107.74,
109.07, 113.11, 118.54, 118.64, 120.89, 126.86, 128.83, 139.92, 144.02, 149.18, 157.60, 166.20,
176.91. MS (ESI) m/z = 406.0 ([M-H]-),  HRMS for C18H14Cl2N3O4: calculated 406.0356, found
406.0371. HPLC: Phenomenex Luna C18 column (5 µm, 4.6 × 250 mm); mobile phase: 10-70%
of acetonitrile in phosphate buffer (pH = 6.8) in 15 min, 70% acetonitrile to 25 min; flow rate 1.0
mL/min; injection volume: 10 μL; tR: 15.443 min (98.6% at 280 nm).
Screening against PAINS
To evaluate  a  library  of  the  synthesized  compounds  against  PAINS,  all  tested  compounds  were
screened against the PAINS filter using the online tool http://www.cbligand.org/PAINS/. All
compounds passed the PAINS filter.
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